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Abstract 
 
Obesity is a growing epidemic but the cellular and molecular mechanisms underlying obesity are 
still not well understood. Mutations in the adaptor protein SH2B1 have been identified in 
individuals with severe early-onset childhood obesity, insulin resistance, and hyperphagia. 
Adaptor proteins have protein binding domains that link protein binding partners and therefore 
facilitate the creation of larger signaling complexes. This phenotype is also seen in mice lacking 
SH2B1 (SH2B1-KO mice). Furthermore, experiments using SH2B1-KO mice and cultured 
neurons suggest that neuronal SH2B1 is critical for this phenotype. Three of the human obesity-
associated mutations are located in the pleckstrin homology (PH) domain of SH2B1, suggesting 
that the PH domain is important for the overall function of SH2B1. The aims of this thesis work 
were to gain insight into how SH2B1 regulates energy balance and glucose metabolism, and the 
contribution of its PH domain to these functions by using two novel mouse models. The first 
model contained one of the human obesity-associated mutations (P322S). Body weight, food 
intake, glucose tolerance and insulin tolerance were not substantially altered by the P322S 
mutation when mice were fed normal chow. However, the P322S mutation decreased glucose 
tolerance in mice challenged by a high fat diet. No effect on insulin tolerance was noted. In 
contrast, a second mouse model with a two-amino acid deletion (ΔP317,R318) in the PH domain 
of SH2B1 showed an obese phenotype. The ΔP317,R318 mice showed significantly increased 
body weight, adiposity, plasma leptin levels and plasma insulin levels, and decreased glucose 
and insulin tolerance. In females, the reduced glucose tolerance and increased plasma insulin 
levels appeared even before the onset of obesity, suggesting that the ΔP317, R318 mutation 
 xii 
results in impaired glucose homeostasis independent of the obese phenotype. At the cellular 
level, deleting P317, R318 changed the localization of SH2B1b from being primarily in the 
cytoplasm and plasma membrane to being primarily in the nucleus. Deleting P317, R318 also 
impaired the ability of SH2B1b to enhance nerve growth factor-induced neurite outgrowth in 
preneuronal PC12 cells. This work provides evidence that the PH domain is a key regulator of 
SH2B1 subcellular localization, neurite outgrowth, and the control of energy balance and glucose 
homeostasis.  
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Chapter 1 Introduction 
 
The Adaptor Protein SH2B1  
Adaptor proteins form part of the signaling cascade downstream of cell surface receptors. 
Adaptor proteins are diverse proteins composed of multiple modular interaction domains (1). 
They play a role in helping to relay messages from the plasma membrane to the nucleus and 
other parts of the cell by serving as docking sites for multiple protein partners in the cascade. 
Their resulting proximity allows proteins in the cascade to find their partners quickly. Some 
adaptor proteins are docked by proteins in the cascade even before an activated membrane 
receptor sends a message to them. However, other adaptor proteins remain unloaded until a 
message from an activated membrane receptor reaches them and then they are docked by other 
proteins in the cascade. Some of these cell surface receptors include receptor tyrosine kinases. 
Ligand binding activates the enzymatic activity of these receptor tyrosine kinases producing 
phosphotyrosine residues that can serve as docking sites for proteins with Src homology 2 (SH2) 
domains (2). SH2B1 (SH2-B, PSM) is a member of a family of three adaptor proteins that also 
includes SH2B2 (APS) and SH2B3 (Lnk).  The three proteins share common domains including 
dimerization, pleckstrin homology (PH) and SRC homology 2 (SH2) domains (3-5). The SH2B1 
gene is alternatively spliced into 4 isoforms (α, β, γ, and δ). The isoforms are identical and differ 
only in the C-terminal region after the SH2 domain (Figure 1.1) (6) SH2B1 is recruited to, and 
plays a role in, the signal transduction process of multiple receptor tyrosine kinases including 
receptors for nerve growth factor (NGF) (7,8), brain-derived neurotrophic factor (BDNF) (7), 
insulin receptor (9,10), insulin-like growth factor (IGF-I) (11), glial cell line-derived 
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Figure 1.1 Schematic of the four human SH2B1 isoforms.   
Shown are the proline-rich regions (P), dimerization domain (DD), nuclear localization sequence 
(NLS), nuclear export sequence (NES), pleckstrin homology (PH) domain, Src-homology 2 
domain (SH2), and tyrosines (Y). Unique C-terminal tails are depicted in different colors. 
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neurotrophic factor (GDNF) (12), platelet-derived growth factor (PDGF) (13), and fibroblast 
growth factor (FGF) (14). SH2B1 is also recruited to activated JAK family members complexed 
to ligand-bound cytokine family receptors (15-18).  
Mechanisms of interaction of SH2B1 with different receptors 
The mechanisms by which SH2B1 interacts with these different receptors and mediates 
signal transduction have been investigated to varying degrees. In this thesis, I will limit my 
discussion to receptors for NGF (TrkA), BDNF (TrkB), leptin (in complex with JAK2), insulin, 
and IGF-1 because those are the most pertinent to my project. SH2B1 has been implicated in 
TrkA and TrkB signaling. SH2B1b/g and family member SH2B2 were identified to interact with 
TrkA and TrkB in yeast two-hybrid screens (7,17). SH2B1a, b and g have been shown to co-
precipitate with active TrkA and SH2B1b with TrkB (19,7,13,20).  NGF and BDNF stimulation 
lead to the dimerization of TrkA and TrkB, respectively (21) and subsequent 
autophosphorylation of several tyrosines in the cytoplasmic domain of TrkA and TrkB (22). The 
interaction of SH2B1b/g  or SH2B2 with TrkA takes place via phosphorylated tyrosines in the 
kinase activation loop of TrkA (7,17). This phosphotyrosine-dependent interaction between 
SH2B1 and TrkA was confirmed via GST pull down assays in cells treated with NGF 
(interaction was not seen in cells without treatment). The SH2 domain appears to be required for 
this interaction since it was not seen when the SH2 domain was mutated (8). I helped show that 
in response to NGF, TrkA phosphorylates tyrosine 753 in SH2B1a and tyrosines 55 and 439 in 
both SH2B1a and SH2B1b (19). I have also shown that SH2B1b is phosphorylated by TrkB 
(data not shown) but have not yet identified the sites of phosphorylation. While SH2B1b and g 
appear to have similar functions in vitro, Joe et al. (19) showed that SH2B1a has different 
effects on NGF signaling. In contrast to the b tail, the unique a tail inhibits the ability of SH2B1 
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to: 1) cycle through the nucleus; 2) enhance NGF-mediated neurite outgrowth; 3) enhance NGF-
mediated gene expression; 4) enhance  phosphorylation of AKT and phospholipase C gamma 
(PLC-g); and 5) enhance autophosphorylation of TrkA. The function of SH2B1a appears to be 
regulated by phosphorylation of tyrosine 753 in the C-terminal tail since the functions listed 
above were restored when tyrosine 753 was mutated to a phenylalanine (Y753F). Furthermore, 
SH2B1a may act as an inhibitor of the actions mediated by SH2B1b. Co-expression of SH2B1a 
inhibited the ability of SH2B1b to enhance neurite outgrowth. This was not the case when 
SH2B1a Y753F was co-expressed with SH2B1b.  
Shc and PLC-g are phosphorylated in response to NGF and recruited to TrkA (7,8). 
Phosphorylation of PLC-g leads to activation of its enzymatic activity (23). However, tyrosyl 
phosphorylation of SH2B1 is thought to create docking sites for the formation of protein 
complexes at the receptor which in turn mediate signal transduction cascades. Tyrosyl 
phosphorylation of Shc by TrkA results in the recruitment of Grb2-SOS complexes leading to the 
activation of the Ras-ERK signaling cascade (24,22). SH2B1g has been reported to  
interact with Grb2 by one group (7) which raises the possibility that SH2B1 may be playing a 
similar role as Shc in signaling by NGF.  
SH2B1 function in neuronal differentiation and survival  
SH2B1b and g  have been implicated in NGF- and BDNF-induced neuronal 
differentiation and survival. Overexpression of SH2B1b/g  enhances NGF-induced neurite 
outgrowth in neuron-like PC12 cells while knockdown of all 4 isoforms of SH2B1 by shRNA 
significantly decreases NGF-induced neurite outgrowth (25). Interestingly, unlike overexpression 
of SH2B1b/g,  overexpression of SH2B1a does not enhance the ability of NGF to promote 
neurite outgrowth in PC12 cells (26). Furthermore, rat neonatal sympathetic neurons cultured 
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with NGF had significantly reduced survival rates when anti-SH2B1 antibodies were injected 
intracellularly to reduce the activity of endogenous SH2B1 (7). Sympathetic neurons also 
showed degeneration of the axons when transfected with cDNA encoding a truncated SH2B1 
mutant while overexpression of SH2B1g promoted long, branched axonal growths (7).  Qian has 
hypothesized that SH2B1g  is able to promote neuronal differentiation by increasing TrkA 
activity, recruiting Grb2 and initiating Ras-dependent signaling, resulting in prolonged ERK 1/2 
phosphorylation (7). However, Rui et al. provide evidence that SH2B1b may be promoting 
neuronal differentiation by a different mechanism. SH2B1b was shown to enhance neuronal 
differentiation in PC12 cells while SH2B1b R555E (mutant lacking the SH2 domain) inhibited 
neuronal differentiation (13).  However, neither SH2B1b nor SH2B1b R555E altered NGF-
induced TrkA autophosphorylation or phosphorylation of downstream proteins including 
ERK1/2 (13), suggesting that SH2B1b could be regulating NGF-induced neuronal differentiation 
through a different pathway and may not be directly activating TrkA.  
BDNF and TrkB are highly expressed in the central nervous system (CNS) (brain and 
spinal cord) and peripheral nervous system (PNS) (cranial and spinal ganglia) and have been 
shown to play a role in neurite outgrowth, neuronal survival, and growth. shRNA knock-down of 
SH2B1 decreases BDNF-induced neurite outgrowth and branching in neonatal cortical neurons 
while overexpression of SH2B1b enhances BDNF-induced neurite outgrowth and branching in 
hippocampal neurons (20). Similarly, SH2B1 knock-down in PC12 cells stably expressing TrkB 
results in decreased neurite outgrowth, while overexpression of SH2B1b enhances BDNF-
induced neurite outgrowth (20). The SH2 domain seems to be required for the function of 
SH2B1b in enhancing BDNF-induced neurite outgrowth since this function was significantly 
impaired when PC12 cells stably expressed the SH2B1b R555E mutant lacking the SH2 domain 
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(20). Shih et al. (20) also showed that pharmacologic inhibitors that prevent phosphorylation of 
ERK 1/2 or AKT inhibit the ability of SH2B1b to enhance BDNF-induced neurite outgrowth 
indicating that the MEK-ERK and PI3K-AKT signaling pathways are required for SH2B1 
enhancement of BDNF-induced neurite outgrowth. However, they do not clarify whether 
SH2B1b actually acts via these pathways. SH2B1 also mediates signals for other neurotrophic 
factors including GDNF. SH2B1 has been shown to interact with the co-receptor for GDNF, 
RET, and facilitates GDNF-induced neurite outgrowth in PC12 cells and mesencephalic neurons 
(12). Thus, SH2B1 has a broad role in enhancing neurotrophic signaling and development.  
Nuclear localization of SH2B1  
While the SH2 domain has been shown to be important for the interaction of SH2B1 with 
different receptors at the plasma membrane, SH2B1b has been shown to cycle through the 
nucleus. A nuclear localization sequence (NLS) (25) and a nuclear-export sequence (NES) 
shared by all 4 isoforms were identified (27). At steady state, SH2B1b localizes to the plasma 
membrane and to the cytosol (28) but when cells are treated with the nuclear export inhibitor 
leptomycin B, SH2B1b accumulates in the nucleus (27). When the NES is mutated or deleted, 
SH2B1b also accumulates in the nucleus (27). These results indicate that at steady state, the rate 
of nuclear export of SH2B1b exceeds the rate of nuclear import. When either the NES or the 
NLS are mutated, SH2B1b loses its ability to enhance neurite outgrowth, suggesting cycling 
through the nucleus is important for SH2B1b enhancement of NGF-induced neurite outgrowth. 
The NLS (as well as the dimerization domain) has also been shown to be important for the 
localization of SH2B1 to the plasma membrane (28).  Phosphorylation of SH2B1b at Ser161 and 
Ser165 near the NLS appear to release SH2B1b from the plasma membrane and enable it to 
translocate to the nucleus (28). A potential role of nuclear SH2B1 is enhancement of gene 
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expression. Expression of a sub-set of NGF-induced genes is enhanced by SH2B1b as shown by 
a microarray analysis of PC12 cells expressing GFP, GFP-SH2B1b WT or GFP-SH2B1b R555E 
before and after NGF treatment (29). SH2B1b-regulated genes included Plaur, Mmp3, and 
Mmp10, which encode for the proteins urokinase plasminogen activator (uPAR), matrix 
metalloproteinase 3 (MMP3), and MMP10, respectively. These proteins have been shown to be 
involved in extracellular matrix degradation crucial for neurite outgrowth in differentiating 
neurons (30-33). uPAR binds the inactive pro-form of urokinase plasminogen activator (pro-
uPA) which is then cleaved by cathepsins and becomes activated. Activated uPA cleaves inactive 
plasminogen to form enzymatically active plasmin, which can then cleave inactive pro-MMPs to 
form active MMPs. This pathway has been implicated in neurite outgrowth and cell 
differentiation (34). uPAR is also considered an early NGF response gene whose function may 
be required to induce secondary response genes important for neuronal differentiation including 
Mmp3 (31,35). When the NLS of SH2B1b is mutated, the ability of SH2B1to promote NGF-
induced expression of these genes is impaired. The finding that mutating the NLS and/or NES 
impairs the ability of SH2B1b to enhance NGF-induced gene expression and neurite outgrowth 
suggest that shuttling in and out of the nucleus seems to be important for at least some of the 
functions of SH2B1. 
SH2B1 and JAK2 
The interaction of SH2B1 and JAK2 and the mechanism by which SH2B1 affects 
signaling by JAK2 has been widely investigated. SH2B1 has been shown to bind to activated 
JAK2 via the SH2 domain of SH2B1 and phosphotyrosine 813 in JAK2 (36). Binding of SH2B1 
to JAK2 in 293T cells has been shown to enhance activation and autophosphorylation of JAK2. 
Two proposed mechanisms have been hypothesized for how SH2B1 enhances JAK2 activity. 
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One is that dimerization of SH2B1 leads to dimerization of JAK2 which enhances JAK2 activity 
(15). The other one is that SH2B1 binds to active and autophosphorylated JAK2 which leads to a 
conformational change that keeps JAK2 in an active state (37). In support of the second 
mechanism, only the SH2 domain of SH2B1β, which lacks the SH2B1 dimerization domain, has 
to be bound to JAK2 to increase its activity. Mutational analysis suggests that SH2B1 directly 
increases JAK2 activity without competing for an inhibitor or recruiting another activator to 
enhance JAK2 activity. JAK2 has been shown to phosphorylate SH2B1β on tyrosines 439 and 
494 (38), suggesting that its phosphorylation by JAK2 may allow it to recruit SH2 domain-
containing proteins.  
JAK2 is known to interact with the receptor for the satiety hormone leptin, LEPRb. 
Leptin binds to its receptor, which activates JAK2, leading to the initiation of downstream 
pathways including STAT3 and the IRS/phosphatidylinositol 3 kinase (PI3K) pathways (39-41). 
Disruption of these pathways has been associated with obesity in mice (42). The function of 
SH2B1 in modulating leptin action important for energy balance will be discussed in a later 
section of this chapter.   
Role of SH2B1 in insulin and IGF-1 signaling 
The role of SH2B1 in insulin and IGF-1 signaling has been investigated in vitro and in 
vivo. SH2B1 has been shown to bind to phosphotyrosines in the activation loop of the insulin 
receptor via its SH2 domain and become tyrosyl phosphorylated (43,9,44,10). SH2B1 enhances 
insulin receptor activity and cellular responses, including mitogenesis and glucose uptake 
(45,46). Overexpression of SH2B1 isoforms stimulates insulin receptor activity leading to 
increased IRS phosphorylation and PI3K signaling, as well as extracellular regulated kinase 
(ERK) signaling (47,48,10). SH2B1 expression delays dephosphorylation of insulin receptor and 
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IRS (47) and protects IRS from phosphatases (48). The role of SH2B1 in insulin sensitivity and 
glucose homeostasis in vivo will be discussed in another section of this chapter.  
SH2B1 also associates, via its SH2 domain, with the related IGF-I receptor (49,11). 
Insulin receptor and IGF-I receptor belong to the same family of receptors and major cellular 
targets are shared between the two including IRS-1, IRS-2, IRS-3, and Shc (50-53). SH2B1 has 
been suggested to enhance IGF-I actions important for the growth and maturation of the ovaries 
in mice (49).  
SH2B2 and SH2B3 family members 
As mentioned previously, SH2B1 is one of a family of three proteins. The other two are 
SH2B2/APS and SH2B3/LNK. These proteins have conserved structures of a dimerization, PH, 
and SH domain. Furthermore, these family members share high sequence homology. SH2B1 is 
ubiquitously expressed in peripheral tissues and the central nervous system.  Like SH2B1, 
SH2B2 is widely expressed in multiple tissues including leptin and insulin targets (brain, liver, 
muscle, and adipose tissue) (54-56). SH2B3 is found primarily in hematopoietic cells (57). 
SH2B1 and SH2B2 are able to form hetero- and homo-dimers via their N-terminal dimerization 
domains. SH2B2, like SH2B1, is involved in mediating neurotrophic signaling. Similar to 
SH2B1, SH2B2 is able to bind phosphotyrosines 679, 683, and 684 in TrkA in response to NGF, 
interact with TrkB in response to BDNF, be phosphorylated by both TrkA and TrkB, and 
promote neurite outgrowth in PC12 cells (7). Interestingly, SH2B3 has been shown to have the 
opposite effect of SH2B1 and SH2B2. It inhibits NGF-induced neurite outgrowth in PC12 cells 
and cortical neurons (58). Furthermore, overexpression of SH2B3 reduces the interaction 
between SH2B1b and TrkA (58). The inhibitory role of SH2B3 in NGF signaling suggests that 
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while SH2B1 and SH2B2 are positive regulators of neurotrophic factor-induced neurite 
outgrowth, SH2B3 may be an inhibitor competing for Trk binding.  
SH2B2 and JAK2 
In the context of cytokine receptor signaling via JAK2, like SH2B1, SH2B2 binds via its 
SH2 domain to phosphotyrosine 813 in JAK2, potentiating the activity of JAK2 overexpressed in 
cultured cells (16,17,59). However, compared to SH2B1, SH2B2 only modestly activates 
overexpressed JAK2 compared to the robust activation of JAK2 by SH2B1 (60,16). The fact that 
SH2B2 is recruited to JAK2 raises the possibility that SH2B2, like SH2B1, may regulate leptin 
sensitivity in mice. However, SH2B2-deficient mice did not show altered body weight, feeding, 
energy expenditure, adiposity, or plasma leptin levels with either a standard chow or a high fat 
diet (61). These findings suggest that SH2B2 does not play a major role in leptin regulation of 
energy balance and adiposity.  
SH2B2 and insulin signaling 
 Similar to SH2B1, SH2B2 seems to play a role in the regulation of insulin signaling. 
SH2B2 binds to the insulin receptor (62) and SH2B2 becomes tyrosyl phosphorylated to an even 
greater extent than SH2B1 in response to insulin (47). Moreover, the insulin receptor 
phosphorylates SH2B2 at Tyr618, which binds directly to c-Cbl (63). SH2B2 is required for 
tyrosine phosphorylation of c-Cbl by the insulin receptor and subsequent activation of the c-Cbl 
pathway, which has been reported to be required for insulin-stimulated Glut4 translocation to the 
plasma membrane and glucose uptake in adipocytes (64-66,63). Also, like SH2B1, SH2B2 binds 
to the activated IGF-I receptor and is phosphorylated by IGF-1 receptor (67). To complicate 
things further, the Rui lab identified a new isoform of SH2B2. This new isoform, SH2B2b, has a 
dimerization domain and PH domain but lacks an SH2 domain (68). SH2B2b was shown to bind 
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to SH2B2 (renamed by the authors as SH2B2a) and SH2B1 in vitro and in intact cells and to 
attenuate the ability of SH2B2a and SH2B1 to activate JAK2 and insulin signaling, including the 
phosphorylation of downstream target IRS1 (68). SH2B2b may be an endogenous inhibitor of 
SH2B2a and/or SH2B1 by acting as a negative regulator of JAK2. In contrast to SH2B1, 
deletion of SH2B2 increases insulin sensitivity in mice (55). However, SH2B2 does not seem to 
affect high fat diet (HFD)-induced insulin resistance and reduced glucose tolerance (61). 
Furthermore, deleting Sh2b2 in Sh2b1 KO mice does not further aggravate insulin resistance 
compared to Sh2b1 KO mice (61). Thus, unlike SH2B1, SH2B2 does not seem to be required for 
the maintenance of glucose homeostasis or energy balance.  
Role of SH2B2 in erythropoietin signaling 
Tyrosyl phosphorylation of SH2B2, presumably through JAKs, is stimulated by ligands 
other than leptin, including erythropoietin (EPO), interleukin 5 (IL-5), IL-3, and granulocyte-
macrophage colony stimulating factor (69,70,67). EPO and EPO receptor are crucial for the 
production of red blood cells. EPO activates JAK2 and the activated JAK2 phosphorylates 
tyrosines in EPO receptor which leads to activation of signal transducers and activators of 
transcription 5 (STAT5), and the RAS/mitogen activated protein kinase (MAPK) and PI3K/AKT 
pathways (71). SH2B2 has been shown to bind via its SH2 domain to phosphotyrosine 343 of 
EPO receptors (70) and is phosphorylated on tyrosine 618 which is able to bind to c-Cbl. SH2B2 
is therefore able to recruit c-Cbl E3 ligase to EPO receptors, which results in the inhibition of 
JAK2/STAT5 pathway in hematopoietic cell lines (70). SH2B2 is also known to co-localize with 
B cell antigen receptors (BCRs) and negatively regulate BCR signaling, presumably as a 
consequence of phosphorylation of tyrosines on SH2B2 (72,69,5). Whereas deletion of SH2B1 
does not seem to affect the development of T and B lymphocytes and mast cells (49), Sh2b2 KO 
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mice show increased B-1 cell number (72,69) and deletion of SH2B2 in mast cells leads to 
increased degranulation, a key process that releases antimicrobial cytotoxic molecules (73). 
Conversely, overexpression of SH2B2 in lymphocytes impairs BCR-induced B cell proliferation 
(72) and overexpression of SH2B2 in mice reduces the number of B-1 cells (72,69). These 
findings suggest that SH2B2 is involved in the regulation of signaling of certain cytokines and 
immune responses, more specifically serving as a negative regulator of a subset of immune cells. 
SH2B3 
While SH2B2 shares many functions with SH2B1, curiously SH2B3 seems to have 
opposite functions of SH2B1. Like SH2B1 and SH2B2, SH2B3 can also form homo dimers 
when it is over expressed in vitro (74). SH2B3 is known for its role in regulating cytokine 
signaling in lymphohematopoiesis (Gery and Koeffler 2013) but recently it was shown to play a 
role in adipose inflammation and pathogenesis of diabetes. SH2B3-deficient mice showed 
adipose inflammation as well as reduced glucose tolerance and insulin resistance. The reduced 
glucose tolerance phenotype was attributed to expansion and increased activity of interleukin-15-
dependent cells and the JAK/STAT5 pathway in adipose tissue since the phenotype was rescued 
with genetic interleukin-15 deficiency or JAK inhibitor treatment (75). These results indicate that 
SH2B3 regulates glucose homeostasis in adipose tissue by regulating expansion and activation of 
adipose innate-lymphoid tissues. Thus, SH2B3 plays a role in the regulation of glucose 
homoeostasis although it may be in a different fashion than the role of SH2B1 (discussed later).  
Role of SH2B3 in hematopoiesis  
Unlike SH2B1, SH2B3 has been shown to play a major role in hematopoiesis. SH2B3 is 
expressed in hematopoietic cells and has been implicated in the integration and regulation of 
multiple signaling events. Like SH2B1 and SH2B2, SH2B3 interacts via its SH2 domain with 
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EPO receptor and JAK2 (76-78). Functional inactivation studies revealed that its SH2 domain is 
important for the inhibitory function of SH2B3. The PH domain also seems to be important for 
its activity (79,74,78). SH2B3-deficient mice show inhibition of the proliferation of 
hematopoietic stem cells, B lymphocytes, and myeloid progenitors (57,80,81). Mice lacking 
SH2B3 show features of myeloproliferative disorders, presumably due in part to hypersensitivity 
to cytokines. These mice also show increased hematopoietic stem cells with enhanced self-
renewal capacity, suggesting that SH2B3 controls hematopoietic stem cell numbers by regulating 
quiescence, cell self-renewal, proliferation, and apoptosis (82).  SH2B3-deficient mice also 
revealed a role for SH2B3 in B-cell proliferation. These mice showed selective expansion of pro 
and pre-B and immature B cells in bone marrow and spleen (80). SH2B3 has also been shown to 
inhibit erythropoiesis (78). Like SH2B1, SH2B3 binds to phosphotyrosine 813 of activated JAK2 
and to a lesser extent to phosphotyrosine 613 (76). This allows SH2B3 to downregulate the 
catalytic activity of JAK2 (76). SH2B3 also binds to non-phosphorylated JAK2 via its N-
terminal domain and maintains the kinase in an inactive state in the absence of cytokine 
stimulation (83). Thus, SH2B3 is a negative regulator of EPO signaling by downregulating JAK2 
activation.  
PH domain of SH2B3 and myeloproliferative neoplasms 
Constitutively active JAK2 has been associated with pathogenesis of myeloproliferative 
neoplasms, polycythemia vera, essential thrombocythemia, and primary myelofibrosis (84). 
Aberrant JAK-STAT signaling in myeloproliferative neoplasms has been attributed to 
JAK2V617F mutation in over 50% of the cases of polycythemia vera, primary myelofibrosis, 
and essential thrombocythemia. SH2B3 has been shown to downregulate JAK2V617F in vitro 
(85). In vivo, in a transduction-transplant murine model, SH2B3 deficiency was found to 
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aggravate development of myeloproliferative neoplasms induced by JAK2V617F (10). 
Interaction between SH2B3 and JAK2V617F was required to restrain polycythemia vera/primary 
myelofibrosis expression in this transduction-transplant model. Interestingly, mutations in the PH 
domain and SH2 domain or PH domain alone of SH2B3 have been identified in patients with 
JAK2V617F negative myeloproliferative neoplasms (86). Furthermore, identification of a 
mutational hot spot in the PH domain of SH2B3 in patients with myeloid malignancies suggests 
that this domain may be playing an important role in the inhibitory role of this protein. Similar to 
JAK2V617F, these mutations are associated with expansion of myeloid progenitor population by 
cytokine-responsive pSTAT3/5 expression. Within the last 10 years, at least 11 point mutations 
(E208Q/E, S213R, A215V, G220V/R, A223V, G229S, T274A, D234N, F287S) have been 
identified in the PH domain of SH2B3 in patients with myeloproliferative neoplasms, 
polycythemia vera, essential thrombocythemia and/or primary myelofibrosis (87,88,71,89-91). 
Mutations in the PH domain of SH2B1 have also been identified in patients exhibiting early 
onset childhood obesity (92) and will be discussed further in a later section of this chapter. This 
points to the importance of an intact PH domain for the function of SH2B family members. 
Clustal analysis of the PH domains of SH2B1, SH2B2, and SH2B3 reveals that the PH domains 
are highly-conserved. We took advantage of the high conservation of the PH domain and have 
used NMR from the PH domain of SH2B2 to model the PH domain of SH2B1, which will be 
discussed in Chapter 2.  
Regulation of Body Weight  
Obesity is a growing epidemic but the cellular and molecular mechanisms underlying 
obesity and associated co-morbidities like diabetes are still not well understood. A complete 
understanding of the molecular mechanisms underlying obesity is important for the development 
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of new therapeutics. Obesity results from an imbalance of energy intake and energy expenditure. 
Energy balance is primarily regulated by the central nervous system, more specifically, in the 
arcuate nucleus in the hypothalamus, a region of the brain where nutrient, hormonal, and 
neuronal signals are received, coordinated and processed (93,94). The neurons in the arcuate 
nucleus of the hypothalamus connect to other neuronal subpopulations within the hypothalamus 
as well as other brain regions including the paraventricular hypothalamic nucleus (PVH), 
dorsomedial hypothalamus (DMH), lateral hypothalamus (LH), and ventromedial hypothalamus 
(VMH), which allows for a coordinated response (94). Distinct neuronal populations within the 
arcuate nucleus of the hypothalamus sense nutrient status and integrate signals from peripheral 
hormones such as leptin to regulate food intake and energy expenditure (95). This ability to sense 
nutrient status and respond to peripheral hormones is possible due to the close proximity of the 
arcuate nucleus to the median eminence, an organ rich in capillaries that lead to the leaky blood 
brain barrier (BBB), which facilitates transport of peripheral hormonal signals from the blood 
into the brain (96).  Leptin is produced by adipocytes proportional to the energy stores 
(triglycerides) in the body and acts to regulate energy balance by reducing appetite and 
increasing thermogenesis (94). Leptin binds to and activates its long form receptor (LEPRb) in 
the hypothalamus. This activates several intracellular signaling pathways including the STAT3 
and PI3K pathway (97,98). These pathways play a crucial role in mediating leptin regulation of 
energy balance since inhibition of STAT3 or PI3K results in leptin resistance and obesity (99). 
When leptin signaling is genetically disrupted, satiety is impaired, and food intake increases 
(hyperphagia). Several mutations in genes encoding leptin or leptin receptor (LepR) have been 
identified in patients that exhibit extreme obesity and hyperphagia (40,100,101). 
Role of POMC and AgRP/NPY in feeding behavior 
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 Leptin receptor-expressing neurons project to other groups of neurons within the arcuate 
nucleus of the hypothalamus that also play a role in the regulation of food intake and energy 
balance. One group are pro-opiomelanocortin (POMC) neurons that produce melanocyte 
stimulating hormone (a-MSH), which is anorexigenic. POMC is cleaved to a-melanocyte-
stimulating hormone (a-MSH), which is released from axons and activates melanocortin 3 and 4 
receptors (MC3/4R) in neurons in a variety of brain regions including the paraventricular 
hypothalamic nucleus, dorsomedial hypothalamus, lateral hypothalamus, and ventromedial 
hypothalamus (102,103). Neurons in these different areas process the information and project to 
neurocircuits distal to the hypothalamus that lead to a decrease in food intake and increase in 
energy expenditure. A second group of leptin receptor-expressing neurons in the arcuate nucleus 
express orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) (104). AgRP is an 
antagonist of MC3R and MC4R (105). NPY stimulates food intake by exerting its effects 
through G-protein coupled receptors including Y1, Y2, Y4, and Y6 (106). High levels of NPY 
are found in obese rodents as well as humans (107), demonstrating a role for NPY in eating 
disorders. AgRP/NPY neurons project to the paraventricular hypothalamic nucleus and lateral 
hypothalamus to mediate their action (108). Thus, leptin decreases food intake and increases 
energy expenditure by activating POMC neurons and inhibiting NPY/AgRP neurons (105). 
Deficiencies in POMC or MC4R expression or activity result in early-onset obesity and 
hyperphagia in humans (109).  
Role of BDNF in feeding behavior 
One downstream mediator thought to be involved in transducing the effects of MC4R 
activation on food intake regulation is BDNF (110). BDNF is a neurotrophic factor shown to 
promote survival of neurons, induce differentiation of neurons in developing and adult central 
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nervous systems and promote the formation of appropriate neuronal connections at central 
synapses (111,112). Activation of MC4R stimulates synthesis of BDNF in dendrites. BDNF has 
been shown to bind to TrkB to regulate feeding and energy expenditure in the paraventricular 
hypothalamic nucleus, ventromedial hypothalamus, and NTS (113-115).  Mutations in children 
with severe obesity have been identified in the genes encoding BDNF and its receptor TrkB 
(116). Conditional deletion of BDNF leads to hyperphagia and obesity in mice (117). The obese 
phenotype seen in BDNF and TrkB mutant animals may be attributed to neurodevelopmental 
anomalies as well as impaired signaling in adults (114). Together, these findings suggest that 
BDNF, like POMC, acts as an anorexigenic signaling molecule. 
 Regulation of Glucose Metabolism  
We obtain glucose primarily from the food that we eat. Stimulation of appetite is driven 
in part by the “hunger hormone” ghrelin. This hormone is primarily released by the stomach, 
although small amounts are also known to be released by the small intestine, pancreas, and brain. 
Ghrelin travels in the bloodstream and acts at the level of the hypothalamus to increase appetite, 
promote food intake, and promote the release of insulin from b-cells in the pancreas (118).  
Insulin and glucagon work together to maintain peripheral glucose homeostasis during 
fed and fasted states, respectively. Food intake and high glucose levels in the blood stimulate the 
pancreas to release insulin from b-cells in the pancreas and inhibit the release of glucagon from 
pancreatic a-cells (118). Insulin and glucagon have opposite roles in the regulation of glucose 
metabolism. Insulin lowers blood glucose by increasing the rate of glucose uptake and utilization 
by tissues in the body including skeletal muscle and adipocytes. It does so by binding to its 
membrane receptor, which is a receptor tyrosine kinase, and causing a cytosolic pool of GLUT4 
glucose transporters to be recruited to the plasma membrane. During the fed state, insulin also 
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acts indirectly to increase glucose uptake in the liver. Insulin activates the enzyme hexokinase, 
which phosphorylates glucose and traps it in the cell. Then, insulin stimulates the storage of 
glucose in the form of glycogen by activating enzymes involved in glycogen synthesis, including 
phosphofructokinase and glycogen synthase. Insulin also suppresses hepatic glucose production 
(119,120). During the fasting state, glucagon is the primary regulator of glucose metabolism in 
the liver. Glucagon stimulates the synthesis of glucose from non-carbohydrate precursors such as 
lactic acid, glycerol, and amino acids. Glucagon also signals the liver to break down glycogen 
into glucose and transport it out into the blood (120).  
Insulin also acts at the level of the central nervous system. Insulin receptors are widely 
expressed in the brain and insulin has been shown to act on NPY/AgRP- as well as POMC- 
expressing neurons (121-123). Insulin action in AgRP/NPY neurons has been shown to be 
required for insulin to suppress hepatic glucose production during hyperinsulinemic-euglycemic 
clamps. This is thought to occur as a consequence of insulin hyperpolarizing AgRP neurons, 
which reduces the release of AgRP and other neurotransmitters, affecting peripheral hepatic 
innervation, which results in increased interleukin (IL)-6 expression in liver cells. IL-6 decreases 
expression of glucose-6-phosphatase and thereby reduces gluconeogenesis in the liver (124). 
Hypothalamic insulin also functions in conjunction with leptin to regulate glucose homeostasis 
(94,125). Deletion of both insulin and leptin receptors in POMC neurons impairs glucose 
homeostasis and leads to systemic insulin resistance (126). However, leptin and insulin appear to 
act on different subpopulations of POMC neurons (127). 
BDNF is highly expressed in neurons in the ventral medial hypothalamus, where it acts 
on neurons to regulate blood glucose levels (128). BDNF reduces hepatic glucose production by 
inhibiting gluconeogenic enzymes such as glucose-6-phosphatase and phosphoenolpyruvate 
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carboxykinase (128). Consistent with this, injection of BDNF into the ventromedial 
hypothalamus lowers fasting blood glucose levels without affecting energy intake. One possible 
mechanism by which this occurs is that BDNF activates SF-1 neurons within the ventromedial 
hypothalamus, which leads to excitation of the neurons in the paraventricular hypothalamus and 
dorsomedial hypothalamus, which in turn decrease glucagon secretion, which decreases liver 
glucose production (129). Interestingly, ventromedial hypothalamus neurons do not only respond 
to BDNF but some also produce BDNF (130). This production of BDNF is upregulated by 
glucose, leptin, and melanocortins (131,114,110). Some studies also postulate that BDNF is a 
mediator of leptin’s action on glucose homeostasis (128). However, the ability of leptin to 
increase peripheral glucose uptake in addition to being able to decrease hepatic glucose 
production points to other key mediators of leptin action independent of BDNF (128).  
Regulation of Body Weight by SH2B1  
Growth, survival, and reproduction of organisms is dependent on nutrient availability and 
storage. Two main forms of nutrients essential for tissues and organs are lipids and glucose. Our 
neuroendocrine system has evolved to maintain lipid and glucose homeostasis. One of the major 
regulators of this metabolic system is the hypothalamus. Given that SH2B1 enhances the 
function of a number of receptors in the hypothalamus that regulate feeding behavior and/or 
energy expenditure (41,61,132,133,17), it is not surprising that in mice, deletion of SH2B1 
results in obesity, leptin resistance and hyperphagia (54,61,48,56).  SH2B1 has been shown to be 
a key molecule that positively regulates leptin sensitivity in vitro (134,54) and leptin signaling in 
hypothalamic neurons (56). Deletion of SH2B1 impaired leptin-stimulated JAK2 activation and 
tyrosine phosphorylation of leptin receptor’s downstream targets of STAT3 and IRS2 in the 
hypothalamus. Because both the STAT3 and IRS2/PI3 kinase pathways are required for leptin 
 20 
regulation of food intake and body weight, reduction in these signaling pathways seem likely to 
contribute to the hyperphagia and obesity seen in the Sh2b1 KO mice. Expression of SH2B1b 
driven by the neuron-specific enolase promoter largely corrects the obese phenotype and leptin 
resistance seen in Sh2b1 KO mice (133). Furthermore, neuron-specific restoration of SH2B1 also 
corrects the overexpression of NPY and AgRP neuropeptides observed in Sh2b1 KO mice. These 
data strongly suggest that decreased neuronal signaling via SH2B1 is important for the obese 
phenotype in Sh2b1 KO mice (133). Consistent with neuronal SH2B1 being critical for SH2B1’s 
effects on energy balance, neuron-specific overexpression of SH2B1b is able to protect against 
high fat diet-induced obesity (133).  
The above studies were carried out using an Sh2b1 KO mouse line produced by the Rui 
lab (Duan 2004, Ren 2005, Ren 2007). Another research group, the Yoshimura lab, generated an 
independent line of Sh2b1 KO mice by homologous recombination (49). This group did not 
report an obese phenotype for the Sh2b1 KO mice. This second line of Sh2b1 KO mice actually 
showed reduced levels of fat mass and adipogenic genes (e.g. PPARg) in white adipose tissue 
(135). These authors concluded that SH2B1 regulates adipogenesis at least in part by regulating 
the insulin/IGF-1/PPARg pathway (135). The discrepancies in the findings between the two 
groups (Rui and Yoshimura) may be due to the background of the mice and/or the conditions in 
which the mice were kept. The Yoshimura lab also reported that the Sh2b1 KO mice are infertile 
(49). The infertility was attributed to immaturity of the reproductive organs and a reduced ability 
of oocytes to respond to follicle stimulating hormone (FSH) and IGF-1 (49). A reduced response 
to IGF-1 in Sh2b1 KO mice would be consistent with in vitro studies showing that SH2B1 can 
bind to the IGF-1 receptor and enhance at least some IGF-1 functions (10,45).  
The ability of SH2B1 to regulate energy balance and glucose metabolism is conserved in 
 21 
species as evolutionarily distant as insects (136).  Disruption of dSH2B, the Drosophila homolog 
of SH2B1, leads to increased whole body glucose and lipid levels in flies. Consistent with 
SH2B1 being an important regulator of energy balance, single nucleotide polymorphisms in the 
SH2B1 gene are associated with obesity in American, Asian, and European populations (137-
140).  Further, studies utilizing the Genetics of Obesity Study (GOOS) cohort have identified 
mutations in SH2B1 in multiple individuals with severe childhood obesity (92,26).  Like the 
Sh2b1 KO mice, these individuals are hyperphagic. Insulin resistance greater than expected from 
the level of obesity is also exhibited in the humans with rare mutations in SH2B1 (92,26).  One 
of the human mutations identified was SH2B1 P322S.  The P322S mutation is located within the 
PH domain of SH2B1 and is therefore present in all four known isoforms of SH2B1. Due to the 
lack of a large number of human patients with the P322S mutation in SH2B1, the metabolic 
phenotype associated with SH2B1 P322S is difficult to investigate in human patients. As 
described in Chapter 2, we have generated and characterized a mouse model that encodes one of 
these obesity-associated human mutations (P322S). We have also generated a second mouse 
model in which SH2B1 has a 2-amino acid deletion. The effects on the cellular actions of SH2B1 
of human obesity-associated mutations identified in SH2B1 will be discussed in Chapter 2 of this 
dissertation. 
Regulation of Glucose Metabolism by SH2B1  
SH2B1 is expressed in multiple tissues involved in glucose homeostasis including the 
brain, pancreas, adipose tissue, liver, and skeletal muscle (141,142,54,68,10). The role of SH2B1 
in these different tissues has been studied to varying degrees, except in the skeletal muscle. To 
investigate the role of SH2B1 in glucose homeostasis, the Rui lab first generated a full body 
Sh2b1 KO mouse model. Consistent with SH2B1 playing a role in glucose homeostasis, deletion 
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of SH2B1 in mice results in insulin resistance (54,56).  Sh2b1 KO mice develop age-dependent 
hyperinsulinemia, hyperglycemia, reduced glucose tolerance and reduced insulin sensitivity (54). 
Deletion of SH2B1 impaired insulin receptor activation, insulin-stimulated tyrosyl 
phosphorylation of IRS1 and IRS2 in the liver, skeletal muscle, and fat, and activation of the 
PI3K pathway (41).  This suggests that the hyperinsulinemia, hyperglycemia, reduced glucose 
tolerance and insulin sensitivity seen in the Sh2b1 KO mice is due, at least in part, to the inability 
of SH2B1 to enhance insulin receptor activation and tyrosine phosphorylation of IRS1 and IRS2. 
Interestingly, neuron-specific restoration of SH2B1 rescued the reduced glucose tolerance, 
insulin resistance, and increased adiposity seen in the Sh2b1 KO mice (56), suggesting that the 
regulation of glucose homeostasis by SH2B1 takes place primarily in the central nervous system.  
The finding that SH2B1 is highly expressed in pancreatic b-cells (10) triggered interest in 
studying the role of SH2B1in the regulation of glucose homeostasis within the pancreas. Glucose 
homeostasis requires the secretion of insulin from pancreatic b-cells, which promotes glucose 
uptake in skeletal muscle and adipose tissue and inhibits hepatic gluconeogenesis. Both insulin 
and IGF-1 promote b-cell expansion by stimulating b-cell proliferation and inhibiting b-cell 
death (143-145). Pancreas-specific deletion of SH2B1 results in impaired insulin secretion, b-
cell survival, b-cell proliferation, islet expansion, and glucose tolerance in mice fed a high fat 
diet (142).  Since SH2B1 has been shown to be required for the activation of the PI3K/Akt 
pathway in b-cells  in vitro and in vivo (142), the impaired glucose tolerance phenotype may be 
due, at least in part, to impaired PI3K/Akt signaling in b-cells.   
The Bernal-Mizrachi lab further investigated the role of SH2B1 in glucose homeostasis in 
b-cells.  Nutrient environment in states of overnutrition such as in obesity are known to play a 
role in the adaptation of b-cells to insulin resistance. One of the molecules responsible for 
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integrating signals from nutrients and growth factors to regulate b-cell size and proliferation is 
the mammalian target of rapamycin complex 1 (mTORC1) (143,146). mTORC1 controls b-cell 
growth and proliferation through phosphorylation of 4E-binding proteins (4E-BP) (147). 4E-BP2 
deletion in mice induces translation of SH2B1 and promotes the formation of an SH2B1 complex 
with IRS2 and JAK2, preventing IRS2 ubiquitination. This suggests that SH2B1 is a major 
regulator of IRS2 stability. Increased IRS2 stability would be expected to increase cell cycle 
progression of b-cells, b-cell survival, and b-cell mass (148).  
b-cells secrete insulin in response to high glucose blood levels such as those after a meal. 
Insulin expression and secretion are regulated by nutrients and hormones. SH2B1 is one of the 
proteins that mediate insulin synthesis and secretion. Knockdown of SH2B1 reduced insulin 
expression, insulin content, and glucose-stimulated insulin secretion in both rat INS 832/13 b-
cells and in mouse islets (141). Similarly, heterozygous deletion of SH2B1 aggravates the 
decreased pancreatic insulin content and plasma insulin levels in leptin-deficient ob/ob mice. 
Overexpression of JAK2, the kinase that mediates the action of the leptin receptor, increased the 
activity of an insulin promoter, and SH2B1 enhanced that ability (141). SH2B1 also increases the 
expression of transcription factor Pdx1, which activates the insulin promoter and insulin 
expression in b-cells (141).  These findings suggest that SH2B1 promotes insulin synthesis and 
secretion in b-cells by enhancing JAK2 activation and Pdx1 expression.  
Since the liver is a key organ in controlling glucose homeostasis and SH2B1 is highly 
expressed in the liver, the Rui lab investigated the role of SH2B1 in the function of the liver to 
regulate glucose homeostasis. The liver produces glucose through gluconeogenesis and 
glycogenolysis. This key role is essential to provide glucose  to vital organs, including the brain, 
during fasting periods to meet their metabolic demands. Insulin controls glucose homeostasis by 
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stimulating glucose uptake and by suppressing hepatic glucose production. During insulin 
resistance, the ability for insulin to suppress hepatic glucose production is impaired, resulting in 
production of excess glucose, which contributes to hyperglycemia and reduced glucose tolerance 
(149). Rui and colleagues generated mice with specific deletion of SH2B1 in the liver. Blood 
glucose levels, plasma insulin levels, glucose tolerance and insulin sensitivity were normal in 
these mice fed either standard chow or a high fat diet (150). This suggests that SH2B1 in the 
liver does not appear to be required to maintain normal insulin sensitivity and glucose 
metabolism. 
Adult-onset deletion of SH2B1 from the liver reduces hepatic steatosis and expression of 
the lipogenic gene diacylglycerol acyltransferase-2 (DGAT2) while increasing the expression of 
the lipolytic enzyme adipose triglyceride lipase (ATGL) (150). Furthermore, deletion of both 
SH2B1 and SH2B2 in the liver in mice fed a high fat diet reduces very low density lipoprotein 
(VLDL) secretion. VLDL secretion is important for exporting triglycerides from the liver to 
other tissues (150). This ability of liver SH2B1 to regulate adiposity may contribute to the ability 
of SH2B1 to regulate body weight.  
Use of CRISPR-cas9 to Generate Novel Mouse Models 
The ability to modify the genome in a precise and targeted manner is key to determining 
genetic contributions to disease as well as the contributions of specific proteins to normal 
physiological function and disease states.  In recent years, a number of technologies designed to 
modify the genome have emerged, including clustered regularly interspaced short palindromic 
repeats (CRISPR)/cas9 genome editing. CRISPR/cas9 was originally identified in bacteria that 
use it as a defense mechanism against phage infection and plasmid transfer (151). CRISPR/cas9 
has been modified to make it a powerful tool for stimulating targeted double-strand breaks 
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(DSBs) in eukaryotic cells (152). Cas9 nuclease from Streptococcus Pyogenes (Sp) is directed 
via Watson-Crick base pairing by a ~20 nucleotide RNA-guide to any target genomic locus (153-
155). One of the requirements in the selection of the Cas9 target site is the presence of a 
Protospacer Adjacent Motif (PAM) sequence 3’ of the ~20-nucleotide target sequence (156). The 
SpCas9 requires a 5’- NGG PAM sequence. The specificity of the Cas9 depends on the 20 
nucleotide RNA guide. Each base within the 20 nucleotide RNA guide sequence contributes to 
specificity; mismatches between the RNA guide and the complementary target DNA can happen 
depending on the quantity, position, and base identity of the targeted sequences (157). These 
mismatches can lead to potential off-target cleavage activities and random insertions and 
deletions. Several online CRISPR design Tools exist that allow for prediction of off-target 
genomic modifications for each RNA guide including (156). Upon cleavage by cas9, the double-
strand break is repaired by one of two repair mechanisms. Non-homologous end joining (NHEJ) 
is the most common repair mechanism but is prone to errors resulting in random insertions or 
deletions. Homologous directed repair occurs at a lower frequency but is a high-fidelity repair 
mechanism that can be exploited to generate precise modifications at a target locus in the 
presence of an exogenously introduced donor template (156). The donor template can be a 
double-stranded DNA targeting construct with homology arms flanking the insertion sequence or 
a single- stranded DNA oligonucleotide. Single-stranded DNA oligonucleotides provide the 
advantage of being able to make small edits in the genome including single nucleotide mutations 
(158). Using CRISPR/cas9 to make genome edits through homologous directed repair provides a 
more effective method than non-homologous end joining, because unlike non-homologous end 
joining, homologous directed repair generally occurs only in dividing cells (159). This latter 
method was the method I used to create the two mouse models in Chapter 2.  
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Pleckstrin Homology Domains 
PH domains were first identified in the platelet protein pleckstrin (160).  PH domains are 
defined as regions of approximately 100 residues that are involved in signaling, cytoskeletal 
organization, membrane trafficking, and phospholipid processing (161,162).  Structurally, PH 
domains are seven-stranded structures formed by 2 anti-parallel β-sheets curving to form a β-
barrel configuration with a C-terminal α-helix blocking one end of the barrel (163,162).  Early 
investigations of PH domains describe their affinity for phospholipids, however, more recent 
studies (162,164) show that the majority of PH domains do not share this function and that PH 
domains are more versatile than initially thought.  For example, some PH domains have been 
reported to bind via protein-protein interactions to phosphotyrosine- or polyproline helice -
containing peptides (162).  Using truncation analysis, our lab showed previously that the PH 
domain of SH2B1b is not required to localize SH2B1b to the plasma membrane (25).  
Furthermore, in NIH 3T3 cells, live cell translocation experiments showed that the PH domain of 
SH2B1 mainly localizes in the cytoplasm and is not recruited to the plasma membrane of PDGF-
stimulated cells in contrast to PH domains that bind to PIP3 (165).  These results indicate that its 
PH domain does not recruit SH2B1 to an organelle-specific phospholipid, making it likely that 
the PH domain of SH2B1 has a function other than recruiting SH2B1 to phospholipids at the 
plasma membrane.  Consistent with this, a series of experiments using N- and C-terminally 
truncated SH2B1b constructs determined that the PH domain of SH2B1 contributes to the 
binding of SH2B1b to inactive JAK2 (59,18).  Rui et al hypothesized that the prior localization 
of SH2B1b to inactive JAK2 would enhance the likelihood that SH2B1b would subsequently 
bind, via its SH2 domain, to phosphoTyr813 in activated JAK2, an interaction that is essential 
for JAK2-dependent SH2B1b function.  It seems likely that the PH domain of SH2B1 functions 
 27 
in a similar fashion when cells are stimulated by ligands such as leptin that utilize JAK2.  
Nothing is known about how the PH domain of SH2B1 functions within the context of SH2B1 
bound to the other receptors implicated in regulating energy balance or glucose homeostasis such 
as the receptors for insulin, IGF-1, and BDNF.  However, consistent with the importance of an 
intact PH domain for the function of SH2B family members, in patients with myeloproliferative 
neoplasms, more than 11 point mutations have been identified in the highly-conserved PH 
domain of the SH2B1 orthologue SH2B2/Lnk. My studies described in Chapter 2 tested the 
importance of the SH2B1 PH domain in vivo by generating and studying mice containing human 
obesity-associated (P322S) or engineered (in-frame deletion of P317 and R318 (ΔPR)) mutations 
in the SH2B1 PH domain. My results demonstrate that the SH2B1 PH domain plays multiple 
crucial roles in vivo, including the control of energy balance and glucose homeostasis. 
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Chapter 2 Crucial Role of SH2B1 PH Domain Function for the Control of Energy Balance 
and Metabolism 
 
Abstract 
Mutations in the adaptor protein SH2B1 have been identified in individuals with severe 
childhood obesity and insulin resistance, a phenotype seen in mice lacking SH2B1. Three of the 
mutations are in the PH domain of SH2B1, suggesting that this domain is important for SH2B1 
function. Here, we examine the impact of PH domain mutations on SH2B1 regulation of energy 
balance and glucose metabolism. We show that the P322S human obesity-associated mutation 
modestly alters glucose tolerance in mice with diet-induced obesity. A nearby two-amino acid 
deletion leads to an obese phenotype, promotes SH2B1b localization in the nucleus and impairs 
SH2B1b enhancement of neurite outgrowth. These results and structural analysis of a model of 
the PH domain of SH2B1 and SH2B3/Lnk suggest that the PH domain of SH2B1 is a key 
regulator of energy balance and glucose homeostasis, perhaps by promoting proper subcellular 
localization of SH2B1 and enhancing neuronal circuits or function.  
Introduction 
Human patients with mutations in the adaptor protein SH2B1 exhibit severe obesity, 
hyperphagia and insulin resistance disproportionate for their obesity (92,26). Consistent with 
SH2B1 playing a key role in regulating energy balance and glucose homeostasis, SH2B1-/-  mice 
are obese and have impaired glucose homeostasis (54,56).  Expression of Sh2b1b driven by the 
neuron-specific enolase promoter largely corrects the obese and glucose-intolerant phenotypes 
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seen in Sh2b1-/- mice (133), suggesting that decreased neuronal signaling via SH2B1 is important 
for these phenotypes.  
At the cellular level, SH2B1 binds to phosphorylated tyrosines in numerous ligand-
activated receptor tyrosine kinases and JAK family members complexed to cytokine family 
receptors and enhances the function of those receptors (36,132,44,7,10,17,20). Some of these 
receptors, including receptors for the satiety hormone leptin, brain-derived neurotrophic factor 
(BDNF) and insulin reside in the hypothalamus and regulate feeding behavior, energy 
expenditure and/or glucose homeostasis (166).  
The four known isoforms of SH2B1 (Figure 2.1a) share 631 N-terminal amino acids that 
contain dimerization, pleckstrin homology (PH) and SH2 domains, a nuclear localization 
sequence (NLS) and a nuclear export sequence (NES). They differ only in their C-termini 
(27,25,6). The SH2 domain recruits SH2B1 to phosphotyrosines in tyrosine kinases (167). The 
NLS and NES enable SH2B1 to shuttle between the plasma membrane, cytosol, and nucleus. 
The NLS and dimerization domains localize SH2B1 to the plasma membrane (27,25). However, 
the function of the PH domain in SH2B1 remains largely unknown.  
PH domains are the 11th most common domain in the human proteonome (168).  They 
are known mainly for their ability to bind phosphoinositides in plasma membranes and organelle 
membranes (169,170). However, 90-95% of all human PH domains do not bind strongly to 
phosphoinositides (168). Truncation analysis reveals that the PH domain of SH2B1b is not 
required for localization of SH2B1b to the plasma membrane (25,171) nor does the PH domain 
itself localize to the plasma membrane (165).  The findings that 3 human obesity-associated 
mutations are in the PH domain of SH2B1 (92,172,173) and at least 11 point mutations 
associated with myeloproliferative neoplasms are in the PH domain of the SH2B1 orthologue 
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SH2B3/Lnk (86,90) highlight the importance of an intact PH domain for the function of SH2B 
family members.  
Here, we test the importance of the PH domain to SH2B1 regulation of energy balance 
and glucose homeostasis. CRISPR/Cas9 genome editing was used to disrupt the PH domain of 
SH2B1 by introducing the human obesity-associated P322S mutation or a 2-residue deletion of 
P317 and R318 (ΔPR). In mice with diet-induced obesity, P322S modestly impaired glucose 
tolerance. The ΔPR deletion caused SH2B1b to mislocalize to the nucleus, impaired the ability 
of SH2B1b to enhance neurotrophic factor-mediated neurite outgrowth, produced substantial 
obesity, and impaired glucose homeostasis.  Modeling of the structure of the PH domains of 
SH2B1 and SH2B3/Lnk based on NMR structure of SH2B2 with visualization of the locations of 
SH2B1 P322S, the ΔPR deletion, and the human mutations in SH2B3/Lnk identified a regulatory 
hot spot in the PH domains of SH2B family members. Taken together, our results reveal the 
importance of the PH domain of SH2B1 in localizing SH2B1 and regulating energy balance and 
glucose homeostasis. 
Results and Discussion 
Generation of SH2B1 P322S mice 
To gain insight into the role of the PH domain of SH2B1 and the impact of the human 
mutations in SH2B1 on energy balance and glucose metabolism, we used CRISPR-based 
genome editing to introduce the human obesity-associated P322S mutation located in the PH 
domain of SH2B1 into C57BL/6J mice. We chose this mutation for multiple reasons:  1) its 
presence in the PH domain; 2) its strong association with obesity in the proband family (92); 3) 
the obese humans with the P322S mutation are heterozygous for the mutation; 4) its inhibitory 
effect on the ability of SH2B1b to enhance nerve growth factor (NGF)-stimulated neurite 
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outgrowth and growth hormone (GH)-stimulated macrophage motility (92); 5) its evolutionary 
conservation in mammals; 6) the conservation of P322 in the SH2B family member 
SH2B2/APS; and 7) programs that predict whether an amino acid substitution would have an 
impact on the biological function of the target protein (Provean, RRID:SCR_002182; PolyPhen, 
RRID:SCR_013189) predict that the P322S mutation would be “probably damaging”.   To create 
the SH2B1 P322S mouse model, two individual sets of CRISPR/Cas9 guides and donor template 
(Figure 2.1b) were designed using http://tools.genome-engineering.org (156) and injected into 
oocytes from C57BL/6J mice.  The oocytes were then implanted into C57BL/6J mice.  DNA 
sequencing confirmed germline transmission of the Guide 2-mediated P322S edit in the N1 
generation (Figure 2.2a).  Insertion of the P322S mutation does not affect the mRNA levels for 
the four different isoforms of SH2B1 (a, b, g, d) in either in the three tissues tested (brain, liver, 
heart) (Figure 2.2b).  Consistent with results in human tissues showing ubiquitous expression of 
the b and g isoforms (92), mRNA for the b and g isoforms is found in all three tissues from wild-
type (WT), SH2B1 P322S/+ and SH2B1 P322S/P322S mice, although only a minimal amount of 
mRNA for the γ isoform was visible in the brain.  Also, consistent with results using human 
tissues, mRNA for the a and d isoforms are present in the brain tissue, absent in the liver and 
present only to a minor extent in the heart from WT, SH2B1 P322S/+ and SH2B1 P322S/P322S 
mice.  We also examined whether the SH2B1 P322S mutation alters SH2B1 protein levels in 
brain tissue (Figure 2.1c). Immunoblotting whole brain lysates with an antibody made against a 
region of SH2B1 shared by all 4 isoforms (aSH2B1) revealed three bands corresponding to 
SH2B1.  None of the bands were present in brains from SH2B1 KO mice. Based on the 
migration of myc-tagged isoforms of SH2B1 expressed in 293T cells (data not shown), the upper 
band co-migrates with overexpressed SH2B1a and the middle band with overexpressed 
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SH2B1d, while the lower band migrates appropriately for SH2B1b and SH2B1g.  We further 
confirmed that all the observed bands correspond to SH2B1 by immunoprecipitating SH2B1 
from whole brain lysates using aSH2B1 before immunoblotting with aSH2B1 (Figure 2.2c) and 
by immunoblotting with a different polyclonal antibody made against amino acids 1-631 shared 
by all four isoforms (data not shown).  Both the immunoblots of whole brain lysates and of 
protein immunoprecipitated from whole brain lysates using aSH2B1 revealed similar levels and 
profiles of SH2B1 isoforms in brains from WT and P322S/P322S mice, indicating that the 
P322S mutation does not affect the expression of the SH2B1 isoforms. 
 Interestingly, we noticed that as we expanded the SH2B1 P322S mouse colony, the 
P322S/P322S mice were born at approximately half the expected Mendelian ratio (Figure 2.2d).  
The SH2B1 KO mice are infertile, which has been hypothesized to be due to immaturity of the 
reproductive organs and a reduced response in oocytes to follicle stimulating hormone (FSH) and 
IGF-1 (49).  A reduced response to IGF-1 in KO mice would be consistent with in vitro studies 
showing that SH2B1 can bind to the IGF-1 receptor and enhance at least some IGF-1 functions 
(10,45).  The P322S mutation in SH2B1 does not seem to have as drastic an effect on fertility as 
deleting SH2B1 since the P322S/P322S mice are fertile (data not shown).  However, the fact that 
P322S/P322S mice are born at about half of the expected Mendelian ratio suggests that SH2B1 is 
important for implantation and/or the embryonic development of the pups with the P322S/P322S 
mutation.   
The effect of the SH2B1 P322S mutation on body weight, food intake, adiposity, and leptin 
levels 
The amino acid sequence of the PH domain in SH2B1, which contains P322, is 94% 
conserved between mouse and human, suggesting that the P322S mutation in mice would have 
 33 
the same impact on SH2B1 function as the P322S mutation is believed to have in humans.  
Because the P322S SH2B1 mutation in humans was identified in an individual with severe 
childhood obesity (92), we first examined whether the P322S SH2B1 mutation causes obesity in 
mice.  Mice were fed a 9% fat standard chow, individually housed at week 4, and weighed 
weekly for 26 weeks. Male and female homozygote (P322S/P322S) and heterozygote (P322S/+) 
mice showed no statistically significant difference in body weight compared to their sex-matched 
WT littermates (Figure 2.1d).  Due to the low number of homozygous mice generated and 
because in human patients the obese individuals are heterozygous for the P322S SH2B1 
mutation (92), subsequent experiments examined the effect of the P322S mutation in 
heterozygous mice. Consistent with the observed lack of difference in body weight, we found 
that there was no difference in food intake between male or female P322S/+ mice and their sex-
matched WT littermates (Figure 2.1e). Similar to body weight and food intake, fat mass (Figure 
2.1f) and lean mass (Figure 2.3a) of male and female P322S/+ mice assessed at week 30 using 
nuclear magnetic resonance (NMR) were comparable to that of their WT littermates. There was 
also no statistically significant difference in the weight of the brain, heart, kidney, or perigonadal 
fat from male or female P322S/+ mice or testis from P322S/+ male mice due to the P322S 
mutation (Table 2.1).   
SH2B1 has been shown to be a positive regulator of signaling via the satiety hormone 
leptin (56,133).  The primary source of leptin in an animal is adipose tissue.  Although leptin 
levels are generally thought to reflect the amount of adipose tissue present in the animal 
(174,94), if a defect in SH2B1 P322S signaling leads to leptin resistance, then elevated leptin 
levels might compensate for the defect.  However, we detected similar serum levels of leptin 
measured at week 30 between male P322S/+ mice and their respective WT littermates (Figure 
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2.3b).  Thus, in contrast to the obesity and hyperphagia seen in humans with the P322S variant 
(92), our results indicate that the SH2B1 P322S mutation does not appear to detectably affect the 
ability of SH2B1 to regulate energy balance or leptin sensitivity of C57BL/6J mice fed standard 
chow. 
Effect of the P322S mutation in SH2B1 on insulin-regulated glucose metabolism 
In addition to obesity, the human patients with the P322S SH2B1 mutation exhibit a 
disproportionate degree of insulin resistance for their obesity (92).  We therefore examined 
whether glucose metabolism in the P322S/+ mice is impaired.  In 28-week-old mice after a 4-
hour fast, neither male nor female P322S/+ mice fed standard chow showed statistically 
significant differences in basal glucose levels compared to their WT littermates (Figure 2.4a).  
To determine if either glucose tolerance or insulin sensitivity are reduced, glucose tolerance and 
insulin tolerance tests were performed.  To assess glucose tolerance, glucose was injected 
intraperitoneally into 28-week-old mice following a 4-hour fast.  In contrast to what we predicted 
from the human patients, glucose tolerance was not altered in either male or female P322S/+ 
mice (Figure 2.1g & Figure 2.4b).  When insulin tolerance tests were performed in 29-week-old 
mice after a 6-hour fast, the changes in glucose levels after the insulin injection were similarly 
not statistically altered in either male or female P322S/+ mice (Figure 2.1h & Figure 2.4c).  
Plasma insulin levels after an overnight fast were also comparable between 13-week-old male 
P322S/+ mice and their control littermates (Figure 2.1i).  These data suggest that the P322S 
mutation in SH2B1 does not significantly affect glucose metabolism or insulin sensitivity in 
mice fed standard chow. 
The effect of the P322S mutation in SH2B1 on body weight in mice fed a high fat diet  
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Eating a diet that is high in fat is one of the main factors contributing to the development 
of human obesity (175).  We therefore thought it possible that the effect of the P322S mutation in 
SH2B1 on energy balance might only become evident in mice with diet-induced obesity. To test  
this hypothesis, we fed the mice a high fat diet (60% fat) for 24 weeks (weeks 6-30).  Although 
both male and female mice gained significantly more weight on a high fat diet (compare Figure 
2.5a to Fig. 2.1d), neither male nor female P322S/+ mice showed a greater body weight gain than 
their WT littermates (Figure 2.5a). For both male and female mice on a high fat diet, the P322S/+ 
mice and their sex-matched WT littermates also consumed comparable amounts of food, 
assessed in 27-week-old mice (Figure 2.5b). 
In contrast to mice fed normal chow, both male and female mice (29-week-old) fed a 
high fat diet exhibited a modest but statistically significant higher basal glucose level after a 6 
hour fast than their WT littermates (Figure 2.6a).  Consistent with an impaired ability to handle 
glucose, both male and female P322S/+ mice assessed at 28 weeks and fasted for 4 hours 
displayed reduced glucose tolerance in response to an intraperitoneal injection of glucose (Figure 
2.5c). This impaired ability to handle glucose was also detected in female mice when the area 
under the curve was calculated (Figure 2.6b).  In the males, an upward trend was evident 
although the area under the curve did not reach statistical significance when compared to WT 
littermates.  However, despite their decreased glucose tolerance, neither the male nor the female 
P322S/+ mice showed decreased insulin sensitivity compared to their sex-matched WT 
littermates assessed using an insulin tolerance test (Figure 2.5d and Figure 2.6c).  Plasma insulin 
levels obtained after an overnight fast were also not statistically different between P322S/+ mice 
and their sex-matched controls (Figure 2.5e), consistent with the P322S mutation not affecting 
insulin sensitivity.  Because glucose tolerance is impaired by the accumulation of fat (176,177), 
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we evaluated if the reduced glucose tolerance seen in the high-fat-diet-fed P322S/+ mice might 
have resulted from increased adiposity. We analyzed body composition using NMR.  For both 
male and female mice, the P322S/+ mutation did not affect either the level of adiposity (Figure 
2.5f) or lean body mass (Figure 2.7a).  Similarly, the P322S mutation in SH2B1 had no effect on 
the weight of brain, heart, kidney, perigonadal fat or testis (Table 2.2).  These data suggest that in 
mice fed a high fat diet, the P322S mutation in SH2B1 modestly attenuates the positive effect of 
SH2B1 on glucose homeostasis. 
Disruption of the PH domain alters the subcellular localization of SH2B1 
While the P322S mouse did not show the obese phenotype we predicted from the human 
patients, we hypothesized that a different PH domain mutation might result in a more profound 
phenotype and provide insight into the importance of the PH domain of SH2B1 in the regulation 
of energy balance and glucose homeostasis. While making the P322S mouse model, we 
generated a second mouse model in a C57BL/6 background that disrupts the PH domain of 
SH2B1 with a two-amino acid deletion (ΔP317,R318) (ΔPR) (Figure 2.1a). DNA sequencing 
confirmed germline transmission of the ΔPR edit (Figure 2.9a).  We first confirmed that this 
deletion would not significantly affect the ability of SH2B1 to be expressed using an in vitro 
system. We first looked at expression of GFP-SH2B1b vs SH2B1b ΔPR in transiently 
transfected PC12 cells, a cell line that sends out neurite outgrowths and expresses neuron-
specific genes when stimulated by the neurotrophic factor nerve growth factor (NGF) (178).  
Levels of GFP-SH2B1b and GFP-SH2B1b ΔPR were similar (Figure 2.8a), indicating that the 
ΔPR deletion is not, to a significant extent, preventing SH2B1b from being expressed or 
affecting its stability. We next used live cell confocal microscopy of SH2B1b to determine 
whether the two-amino acid deletion alters the subcellular localization of SH2B1b. Figure 2.8b 
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and 2.8c illustrate that GFP-SH2B1b localizes primarily to the plasma membrane and cytoplasm 
of both 293T and PC12 cells, consistent with previous results (28). Surprisingly, in contrast to 
SH2B1b WT, when SH2B1b DPR is expressed in either 293T cells (Figure 2.8b) or PC12 cells 
(Figure 2.8c), some localizes at the plasma membrane but most localizes to the nucleus. 
Although WT SH2B1b has been shown to shuttle between the nucleus and cytoplasm, no 
SH2B1b is visible in the nucleus under steady state conditions (27,28), indicating that the rate of 
nuclear export of SH2B1b must greatly exceed the rate of nuclear import. Interestingly, 293T 
cells expressing GFP-SH2B1β WT showed a nuclear localization after being treated with an 
inhibitor of nuclear export, leptomycin B, however, cycling of GFP- SH2B1β P322S into the 
nucleus was significantly impaired (Doche 2012, Figure 2B and Supplemental Figure 1). The 
nuclear localization of SH2B1b DPR suggests that the DPR mutation alters SH2B1 cycling 
through the nucleus to favor retention in the nucleus.  
We next examined whether the disruption to the PH domain affects the ability of 
SH2B1b to enhance neurotrophic factor-mediated neurite outgrowth. SH2B1b has been shown to 
enhance the ability of neurotrophins such as nerve growth factor (NGF) and BDNF to promote 
neurite outgrowth and/or branching in PC12 cells, hippocampal, and/or cortical neurons 
(29,167,7,8,20). We transiently expressed GFP-SH2B1b WT or GFP-SH2B1b DPR in PC12 
cells, added NGF for two days, and determined the percentage of transfected cells exhibiting 
neurite outgrowths two times the length of the cell body (Figure 2.8d). The DPR mutation 
impairs the ability of SH2B1b to enhance NGF-induced neurite outgrowth. Together, these 
results show that disruption of the PH domain by the DPR mutation alters the subcellular 
distribution of SH2B1b and impairs the ability of SH2B1b to enhance neurotrophic factor-
induced neurite outgrowth. This raises the possibility that the PH domain helps keep SH2B1 out 
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of the nucleus, thereby enhancing SH2B1’s ability to act at the plasma membrane to enhance the 
ability of hormones and neurotrophic factors to stimulate neuron function (e.g., by enhancing the 
formation of appropriate neuronal projections). 
SH2B1 DPR mice develop obesity and impaired glucose metabolism 
Due to the robust and interesting phenotype that the SH2B1 DPR mutant showed at the 
cellular level, we were convinced that SH2B1DPR was an active protein.  We proceeded to 
investigate the effect of the DPR disruption of the PH domain of SH2B1 on energy balance and 
glucose homeostasis in mice. We first determined whether the DPR mutation affects the relative 
abundance of mRNA of the different SH2B1 isoforms in the brain and in peripheral tissue (e.g. 
heart). Like the P322S mutation, the DPR deletion does not appear to affect the relative 
abundance of mRNA of any of the SH2B1 isoforms in either of the tissues tested (Figure 2.10a).  
We also examined whether the DPR deletion alters levels of SH2B1 protein in brain tissue 
(Figure 2.10b). The DPR deletion had only a modest effect on protein levels and no effect on the 
relative levels of the different SH2B1 isoforms in the brain. We also found that in contrast to the 
P322S mice, the DPR mice are born at close to the expected Mendelian frequency (Figure 2.9b).  
Having established that the protein expression of SH2B1 isoforms is not substantially 
affected by the DPR deletion in mice, we turned our attention to the effect of the DPR deletion on 
energy balance and glucose homeostasis. In contrast to the P322S mice, both male and female 
DPR mice fed standard chow exhibited significantly increased body weight and fat mass 
compared to their WT littermates (Figure 2.10c and 2.10d). When body weight was measured 
over time (Figure 2.10e), DPR/DPR and DPR/+ male mice at 20 weeks were 15 grams (>40%) 
and 3 grams heavier, respectively, than their WT littermates and the DPR/DPR female mice were 
approximately 9 grams (~35%) heavier. The weight gain of the male and female DPR/DPR mice 
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was comparable to the weight gain of the KO mice (56,133). To determine if the increased body 
weight seen in the DPR mice was a result of hyperphagia, food intake of individually housed 
mice was monitored from weeks 18-20 (Figure 2.10f). Both the DPR/DPR and DPR/+ male mice 
and DPR/DPR female mice showed statistically significant increased food intake compared to 
their WT littermates. To determine whether energy expenditure is also contributing to the obesity 
seen in the DPR mice, we measured 24-hour oxygen consumption (normalized to lean body 
mass) (Figure 2.10g), respiratory exchange ratio (RER) (Figure 2.11a), locomotor activity in 
both horizontal (activity-x total) (Figure 2.11b) and vertical axis (activity-z total) (Figure 2.11c), 
fat oxidation (data not shown), and glucose oxidation (data not shown) using the Comprehensive 
Lab Animal Monitoring System (CLAMS) in 11-12-week-old mice. The DPR/DPR mice showed 
a modest increase in vertical locomotor activity (Figure 2.11c). However, DPR/DPR and DPR/+ 
male and female mice showed no difference in any of the other parameters compared to their WT 
littermates. These data suggest that the DPR mutation causes obesity in mice primarily as a 
consequence of increased food intake and not decreased energy expenditure.  
Increased weight can be due to increased overall size, lean body mass, adipose tissue, or 
some combination thereof. We therefore used NMR to assess lean body mass and fat mass. Body 
fat mass, assessed in absolute grams, was essentially doubled in both male and female DPR/DPR 
mice and ~50% increased when assessed as a percentage of body weight when compared to their 
WT littermates (Figure 2.12a and Figure 2.13a). Lean mass was much more modestly increased 
in both DPR/DPR male (by ~16%) and female (by ~6%) mice compared to WT littermates 
(Figure 2.13b) and was actually decreased in DPR/DPR male mice when normalized to body 
weight (Figure 2.12b). No statistically significant change in either fat mass or lean mass was 
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seen in DPR/+ male or female mice when compared to WT littermates (Figure 2.12a, 2.12b and 
Figure 2.13a, 2.13b). 
When individual fat depots were dissected and weighed (Table 2.3), inguinal fat mass 
was found to increase by 120% and 20% for the DPR/DPR and DPR/+ male mice, respectively 
and perigonadal fat mass by 50% and 40%, respectively. The increase in inguinal and 
perigonadal fat mass was even more dramatic in the DPR female mice. Inguinal fat mass 
increased by 220% and 40% in the DPR/DPR and DPR/+ female mice, respectively while 
perigonadal fat mass increased by 280% and 60%, respectively. Brown fat was also significantly 
increased in DPR/DPR male mice compared to their WT littermates. In contrast, there was no 
difference in the weight of brain or heart from DPR/+ or DPR/DPR mice vs their WT littermates 
(Table 2.3).  The modest increase in the weight of the liver from male DPR/DPR mice seems 
likely to be due to increased fat deposition resulting from the increased adiposity. These data 
suggest that the increased body weight in the DPR mice is primarily due to increased fat mass. 
Consistent with the increased adiposity observed at 24-26 weeks of age, plasma leptin 
levels were significantly higher in DPR/DPR male and female mice and DPR/+ male mice 
(Figure 2.12c). To confirm that the increased leptin levels are due primarily to increased 
adiposity, we measured leptin concentrations and body composition at a younger age when the 
fat mass of the DPR mice may not have started to accumulate to a level higher than that of their 
littermate controls. Consistent with the elevated leptin levels seen in the 24-26-week old 
DPR/DPR mice being primarily due to elevated adiposity, leptin levels measured in 7-week old 
mice were not elevated in female DPR/DPR and DPR/+ mice and male DPR/+ mice (Figure 
2.14a), which exhibited similar fat and lean body mass compared to their WT littermates at 11-
12 weeks of age (Figure 2.13c, d & 2.14b, 6c).  Only the DPR/DPR male mice, which started to 
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exhibit increased fat mass as early as 6-7 weeks, exhibited elevated leptin levels. Interestingly, 
by the time (12-14 weeks) we sacrificed that cohort of DPR/DPR mice, the perigonadal fat was 
doubled in weight in both males and females compared to littermate controls (Table 2.4). Liver 
weight was also increased in DPR/DPR and DPR/+ female mice compared to control littermates, 
consistent with increased adiposity (Table 2.4). Brain weight was not altered (Table 2.4).  
Disruption of the PH domain in SH2B1 causes hyperglycemia, reduced glucose tolerance, 
and insulin resistance in mice 
To gain insight into whether disruption of the PH domain in SH2B1 also affects SH2B1 
regulation of insulin-regulated glucose metabolism, we measured blood glucose levels after a 4-
hour fast at week 18. Both male and female DPR/DPR mice exhibited statistically significant 
hyperglycemia compared to their WT littermates (Figure 2.16a). Challenging the mice with an 
exogenous bolus of glucose via an intraperitoneal injection confirmed impaired glucose tolerance 
in both male and female DPR/DPR mice and male DPR/+ mice (Figure 2.15a and Figure 2.16b). 
The ability of exogenous insulin to lower blood glucose levels during insulin tolerance tests was 
also significantly impaired in DPR/DPR male mice (Figure 2.15b and Figure 2.16c) but not in 
female DPR/DPR mice or male or female DPR/+ mice. Together, these results suggest that after 
the onset of obesity, the SH2B1 DPR mice have an impaired ability to regulate glucose 
homeostasis.  
Disruption of the PH domain in SH2B1 causes hyperglycemia, hyperinsulinemia, and 
reduced glucose tolerance in mice prior to the onset of obesity 
Because the DPR mutation causes obesity and obesity itself can cause impaired glucose 
homeostasis, we examined whether the DPR deletion causes impaired glucose tolerance 
independent of obesity. At 8 weeks of age, before the onset of adiposity in females and when 
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adiposity as judged by leptin levels was still relatively modest in the males, both the DPR/DPR 
male and female mice showed hyperglycemia compared to their WT littermates after a 4-hour 
fast (Figure 2.17a). Furthermore, the DPR/DPR male and female mice showed reduced glucose 
tolerance compared to their WT littermates when exogenous glucose was administered 
intraperitoneally during a glucose tolerance test (Figure 2.16c and Figure 2.17b). The DPR/+ 
male and female mice tolerated glucose normally (Figure 2.16c and Figure 2.17b). In contrast, 
insulin sensitivity assessed by an insulin tolerance test at week 9 was similar in both DPR/DPR 
and DPR/+ male and female mice compared to their WT littermates (Figure 2.16d and Figure 
2.17c). However, compared to WT littermates, both DPR/DPR male and female mice exhibited 
hyperinsulinemia at 8 weeks of age after a 6 hour fast (Figure 2.16e) suggesting that at this age, 
which is several weeks before the weight of the DPR/PR mice starts to increase above that of the 
WT mice (Figure 2.10e), the DPR mice are starting to develop insulin resistance. Together these 
data suggest that even before the onset of obesity, the disruption of the PH domain by the DPR 
deletion significantly impairs the ability of SH2B1 to regulate glucose homeostasis, in addition 
to impairing energy balance.  
Modeling and analysis of the 3-D structure of the PH domain in the region of P317, R318, 
and P322  
     To gain insight into how the SH2B1 P322S mutation or deletion of residues P317 and 
R318 in SH2B1 might regulate the function of the PH domain in SH2B1, we analyzed the NMR 
structure of the PH domain of the SH2B1 family member SH2B2/APS (1V5M) (179).  Clustal 
analysis of the PH domains of these three SH2B family members reveals that the PH domains are 
highly-conserved and identifies the residues corresponding to the P317 and R318 residues 
responsible for the DPR deletion and the P322S mutation in SH2B1 as P71, K72 and P76 in 
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SH2B2/APS, respectively (Figure 2.18a).  The residues that are homologous or functionally 
homologous (black and cyan) in the ClustalW are colored green in Figure 2.18b-d.  Non-
conserved residues are colored orange.  The minimal number of orange-colored residues in the 
region surrounding the residues P71, K72 and P76 in the SH2B2/APS structure, corresponding to 
P317, R318, and P322S in SH2B1, suggests that the structure in this region will be a good model 
for SH2B1.  In the SH2B2/APS structure, the residues corresponding to P317, R318, and P322S 
in Sh2B1 are on an exterior surface of the PH domain.  This surface is presumably a binding 
interface that interacts with either another region in SH2B1 or another protein (Figure 2.18b).  
Because the residues corresponding to P317 and R318 in SH2B1 (P71 and K72 in SH2B2/APS) 
are on the surface of the PH domain and do not substantially change the direction of the loop, the 
P317, R318 deletion in SH2B1 is not expected to severely damage the structure.  However, the 
deletion would be expected to diminish stabilization of the turn between P71 (P317 in SH2B1) 
and the nearby b-pleated sheet that is provided by the predicted pi stacking between residues 
P317 and F309 in SH2B1 (P71 and F63 in SH2B2/APS).  In addition, the deletion would be 
expected to substantially alter the shape of the interface surface in the region of P317 and R318 
in SH2B1 (P71 and K72 in SH2B2/APS). With respect to the P322S mutation (P76 in 
SH2B2/APS), the proline to serine mutation would be expected to increase the motion of the 
peptide backbone at this residue.  The mutation to serine also opens up the possibility of changes 
due to phosphorylation.                                                       
 Consistent with the importance of an intact PH domain for the function of SH2B family 
members, at least 11 point mutations (E208Q/E, S213R, A215V, G220V/R, A223V, G229S, 
T274A, D234N, F287S) have been identified in the PH domain of the SH2B1 orthologue 
SH2B3/Lnk in patients with the myeloproliferative neoplasms, polycythemia vera (PV), essential 
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thrombocythemia (ET), and/or primary myelofibrosis (PMF) (87,88,71,89-91)(Figure 2.18a).  In 
addition, the mutations E208Q, S213R, A215V, and T274A in SH2B3/Lnk have been identified 
in JAK2 mutation–negative patients with idiopathic erythrocytosis who had normal/subnormal 
erythropoietin levels (71,180).  Residues in the SH2B2/APS structure (C45, L48, A52, and R57) 
that correspond to five of the human mutations in SH2B3/Lnk (G220V, G220R, A223V, G229S, 
and D234N) and V53 in the SH2B2/APS structure that corresponds to the human E229G 
mutation in SH2B1 are in close proximity to the P71, K72 or P76 (P317, R318, or P322 in 
SH2B1 respectively) (Figure 2.18a, c, d).  The concentration of human patient mutations in this 
region, along with the pi stacking and extensive hydrogen bonding that stabilizes this region of 
the PH domain, suggest that small structural changes in this region due to mutation or other 
modification have the potential to produce substantial functional consequences.  In addition, 
beyond the 8 mutation sites discussed above, two additional residues (D31 and A40 [E208Q, 
A215V mutations in SH2B3/Lnk]) are also on the PH domain surface and suggest that this 
surface might be a protein binding interface.  Taken together, the human SH2B3/Lnk mutations 
(G220R, G220V, A223V, G229S, and D234N), the human SH2B1 mutations (E299G and 
P322S) and the P317, R318 deletion in SH2B1 identify a regulatory hot spot in the PH domains 
of the SH2B family members that is critical for the function of the PH domain. 
Discussion 
Although the PH domain is among the most common domains in proteins (162), the 
function of most PH domains remains unknown.  What is known has primarily been gained from 
in vitro studies; few studies have been carried out in animal models in which alterations in the 
PH domain have resulted in identifiable changes in phenotype. The finding here that a relatively 
small deletion in the PH domain, predicted to have only a minor effect on the structure of the PH 
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domain, causes a rather profound effect on SH2B1b localization at the cellular level and energy 
balance and glucose homeostasis at the whole animal level provides some of the first real 
evidence of the importance of this domain in SH2B1 function. While SH2B1b has been shown to 
cycle through the nucleus, it is generally found at the plasma membrane and in the cytoplasm 
(27,167,25).  The dramatic accumulation of SH2B1b DPR in the nucleus indicates that the DPR 
deletion greatly alters the ratio between nuclear import and nuclear export of SH2B1b.  One 
explanation consistent with our structural model of the PH domain of SH2B1 (Figure 2.18) is 
that the DPR mutation alters a putative protein binding interface of SH2B1 and affects the ability 
of the PH domain to bind to another protein or another region of SH2B1.  The resulting altered 
protein-protein interaction either blocks the NES, enhances the accessibility of the NLS, or both.  
The fact that the PH domain is shared among all isoforms of SH2B1 suggests that the PH domain 
of SH2B1 is likely to be similarly critical in determining the subcellular distribution of all the 
isoforms.  We predict that such a drastically altered subcellular distribution would have an 
important impact on the function of each of the different SH2B1 isoforms.  Consistent with this, 
the DPR mutation impairs the ability of SH2B1b to promote neurotrophic factor-induced neurite 
outgrowth of PC12 cells.  Because neurite outgrowth in PC12 cells shares many properties with 
the formation of axons and/or dendrites (178), one possibility for the substantial shift in energy 
balance seen in the DPR mice is an impaired ability of the neurons that regulate feeding behavior 
to form the proper neuronal projections.  Because SH2B1 is recruited to a variety of receptors 
implicated in feeding behavior, including the receptors for leptin (132), insulin (44,10) and 
BDNF (7,20), it will be interesting to determine whether the PH domain of SH2B1 impairs the 
outgrowth of neurons expressing each of these receptors, and whether a change in subcellular 
distribution or some other impaired function responsible for the drastic change in energy balance 
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observed in the SH2B1 DPR mice.  It will also be interesting to determine if the primary effect of 
the PH domain on glucose homeostasis is mediated via SH2B1 acting centrally or peripherally. 
Regarding the P322S mouse, we showed that in mice fed a standard 9% fat diet or a high 
fat diet, the P322S mutation in SH2B1 does not affect body weight, food intake or insulin 
sensitivity of heterozygous mice.  Studies using a smaller cohort (3-4 animals) of homozygous 
mice fed a standard 9% fat diet gave similar results, i.e. no effect of the P322S mutation on body 
weight, food intake or insulin sensitivity in male or female mice (Fig. 1d and data not shown).  
Although the P322S mutation in SH2B1 in mice also did not seem to affect glucose tolerance or 
insulin sensitivity under standard chow conditions, the P322S mutation did decrease glucose 
tolerance when the mice were challenged with a high fat diet.  However, in contrast to humans 
with the P322S mutation and SH2B1 KO mice, the P322S/+ mice did not show decreased 
sensitivity to insulin, as judged by a normal insulin tolerance test.  The finding that pancreas-
specific deletion of SH2B1 in mice impairs glucose tolerance under high fat diet conditions, 
presumably due to increased apoptosis and decreased rate of proliferation of beta cells (142), 
raises the possibility that under high fat diet conditions, the P322S mutation may impair the 
function of SH2B1 in glucose metabolism by diminishing the protective function of SH2B1 in 
beta cells.  The reduced rate of survival of neonatal mice with the P322S mutation in SH2B1 
suggests a further problem with reproduction. Taken together, our data suggest that, in mice, the 
P322S mutation does not replicate the full spectrum of effects seen in humans with the SH2B1 
P322S mutation.  Because environmental factors such as diet, exercise and other behavioral 
patterns greatly increase the prevalence of obesity in a population (181), it is possible that other 
environmental conditions or genetic backgrounds may reveal a phenotype in mice with the 
SH2B1 P322S mutation that more closely resembles the obese, insulin-resistant phenotype 
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ascribed to humans with the P322S mutation.  Our combined studies with the SH2B1 P322S 
mice and the SH2B1DPR mice in conjunction with analysis of the structure of the PH domain of 
SH2B1, SH2B2/APS and SH2B3/Lnk highlight the importance of the PH domain in SH2B1 in a 
variety of cellular and whole animal metabolic functions, and suggest the importance of follow-
up studies at both the cellular and whole animal level.  
Methods 
Study approval  
All procedures were approved by the University Committee on the Use and Care of Animals at 
the University of Michigan and followed the Public Health Service guidelines for the humane 
care and use of experimental animals. 
Animal care 
Mice were housed in ventilated cages under controlled temperature (23°C) on a 12 hour light, 12 
hour dark cycle (from 6:00 to 18:00) in the Unit for Laboratory Animal Medicine at the 
University of Michigan. Mice were fed standard chow (20% protein, 9% fat, PicoLab Mouse 
Diet 20 5058, catalog#0007689) ad libitum with free access to tap water.  
Generation of SH2B1 P322S and DP317, R318 mice 
CRISPR/Cas9 genome editing was used to insert the P322S mutation into mice. The reverse 
complement of the genomic SH2B1 sequence in C57BL/6J mice (accession # NC_000073, GRC 
m38) was used when designing the reagents for CRISPR.  CRISPR/Cas9 genome editing 
requires an RNA guide and a donor template for homology-directed repair.  Two sets of RNA 
guides (Guides 1 and 2) were selected from the guides predicted using the website described in 
Ran et al. (156). Guides were selected that cut within 40 nt of the codon for P322 and had a high 
inverse likelihood of off-target binding.  The guides were expressed using the pX330 vector 
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(152,156). The pX330 vector contains a chimeric guide RNA expression cassette and the 
hSpCas9 expression cassette.  The oligos required for expressing the guides were purchased from 
Integrated DNA Technologies (IDT).  The two oligos for guide 1 (nt 3325-3344) were: (1st 
strand, 5’-AAACcgtaggcgtcccgaccccgtC-3’ containing the reverse complement of the guide 
sequence flanked by an AAAC overhang for subcloning into a Bbs1 site and a 3’ C for initiating 
transcription by U6 polymerase), and (2nd strand, 5’-CACCGacggggtcgggacgcctacg-3’ 
containing the guide sequence flanked by a CACCG overhang for subcloning into a Bbs1 site 
with a G for initiating transcription by U6 polymerase).  The two oligos for guide 2 (nt 3337 -
3356) were: (first strand,  
5’-AAACgaccccgtctcagcattccc-3’ and (2nd strand, 5’-CACCgggaatgctgagacggggtc-3’).  The pair 
of oligos for each guide was annealed, and subcloned into the Bbs1 site in the chimeric guide 
RNA expression cassette in the pX330 vector.  The resulting construct was expressed in DH5a 
cells.  Colonies were selected, DNA isolated, and the sequence verified in the region of the 
inserted guide sequence.  The donor template for homology-directed repair (HDR) (from IDT) 
was designed to code for a mutated version of the 180 nt region between nt 3264-3443 of 
SH2B1.  The donor template introduced the C>T mutation into the codon for P322 to produce 
the human disease mutation, SH2B1 P322S.  Silent mutations were introduced to create a 
diagnostic Xbal site and to disrupt guide RNA binding and prevent further cleavage by Cas9 
following HDR (Fig. 1a).  Top (sense) strand of donor template:  (nt 3264) 5-
gaatggagggagatacagttagatttgacacacc 
aaaaactgattcttcttccctttcccgcgt[guide#1cut site]aggcgtcTAgac[guide#2cut site]cTAg 
ActcagcattTcctgctctactattactgatgtccgcacagccacagccctagagatgcctgacagggagaacacgtttgtggttaaggtag
gaacccca-3’ (nt 3443).  Bottom (antisense) strand: 5’-tggggttcctaccttaacca 
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caaacgtgttctccctgtcaggcatctctagggctgtggctgtgcggacatcagtaatagtagagcaggAaatgctgagTcTAggtcT
Agacgcctacgcgggaaagggaagaagaatcagtttttggtgtgtcaaatctaactgtatctccctccattc-3’.   
The pX330 plasmid containing the guide sequence was purified using an endotoxin-free 
PureLink HiPure maxiprep kit (Life Technologies #K210006).  The plasmid DNA was eluted 
with EB buffer (10 mM Tris, pH 8.5) and further purified using a Qiaprep miniprep column 
(QIAGEN; #27106).  All buffers used with the miniprep column were filtered using Anotop 0.02 
µm filters (Whatman #6809-1002).  The miniprep column was washed with PE buffer.  DNA 
concentrations were determine using a NanoDrop One spectrophotometer (Thermo Scientific).  
DNA (100 µg) eluted from the maxiprep was solubilized in 1.5 ml of PE buffer and loaded onto 
the miniprep column 2X.  The column was washed 4 times with 0.75 ml of PE and the DNA 
eluted with 50 µl of EB buffer.  To prepare the donor template, the oligonucleotides were 
solubilized in microinjection buffer (RNAse-, DNAse-free 10 mM Tris, 0.1 mM EDTA, pH 7.4, 
filtered with Anotop 0.02 µm filters) and annealed.  A Millipore dialysis filter (#VMWP02500) 
was floated shiny side up on 10 ml of microinjection buffer and 75 µl of the annealed template 
subjected to spot dialysis for 45 minutes.  The concentrations of the purified pX330 plasmid 
containing the guide sequence and the donor template were determined.  The constructs and the 
template were diluted with microinjection buffer to 5 ng/µl and 10 ng/µl, respectively, and 
transferred to the University of Michigan Transgenic Animal Model Core for testing in 
blastocysts.  DNA obtained from stage 8 blastocysts was genotyped by PCR followed by 
digestion with XbaI restriction enzyme (see below).  PCR analysis and DNA sequencing showed 
that 8 of 23 Guide 1 and 17 of 27 Guide 2 blastocysts contained the P322S edit.  Each 
guide/template combination was then injected into ~75 oocytes from C57BL/6J mice.  The 
injected oocytes were then implanted into C57BL/6J mice by the University of Michigan 
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Transgenic Animal Model Core.  The genotype of the resulting pups was determined by PCR 
and XbaI digestion, and confirmed by DNA sequencing.  Of the five pups born from mice 
implanted with oocytes injected with Guide 1, 4 pups were wild-type (WT) and 1 pup contained 
an indel.  Of the six pups born from mice implanted with oocytes injected with Guide 2, 2 pups 
contained the P322S edit and 4 pups had indels.  P322S founders were backcrossed against 
C57BL/6J mice to breed out off-target effects.  DNA sequencing confirmed germline 
transmission of the P322S edit (Supplemental Fig. 1a).  N2 mice from one founder were used for 
experiments in Figure 1 and Supplemental Table 1.  N5 mice from the same founder were used 
for experiments in Figure 2 and Supplemental Table 2.  One of the indels encoded SH2B1 
DP317, R318 (DPR).  The DPR founder was backcrossed against C57BL/6J mice to breed out 
off-target effects.  DNA sequencing confirmed the germline transmission of the DPR deletion 
(Supplemental Fig. 2a).  N3 mice were used for experiments in Figures 4-5, Figure 6A-B, and 
Table 1 and N4 mice were used for experiments in Figure 6C-E and Figure 7.  
Genotyping and PCR 
To genotype the mice, tails were collected from mice prior to 21 days of age and boiled at 95°C 
for 1 hour in 75ul Buffer 1 (0.2 mM EDTA, 25 mM NaOH).  Buffer 2 (75ul, 40 mM Tris HCI, 
pH 8.0) was then added (Biotech, 2000). A 556 nt product was amplified from purified mouse 
tail DNA and digested with Xbal (P322S mice) or purified with QIAquick PCR purification kit 
(QIAGEN; #28106)   and submitted for Sanger DNA sequencing at the University of Michigan 
DNA Sequencing Core (P322S and DPR mice). The following primers were used (10 nM final 
concentration)  
5’ –TATTGCTGTCCTGGGTTCAGTGCTAACTGT-3’ and  
5’ -AAGACTCAAAGCCCCCGACATATACTCATC- 3’.   
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To determine relative levels of SH2B1 gene expression, total cellular RNA was extracted using 
TRIzol Reagent (Ambion; Life Technologies). cDNA was synthesized from the RNA using 
Taqman Reverse Transcription Reagent Kit (Applied Bio-Systems; N808-0234) per 
manufacturer’s instructions. PCR was performed using GoTaq DNA polymerase (Promega, 
Catalog #M3005) using the following parameters: 95°C 2 minutes, 95°C 15 seconds, 63°C 30 
seconds, 72°C 1:20 minutes, repeat 42 cycles, 72°C 4 minutes, 4°C. 
PCR primers (each 10 mM concentration) used for detection of all SH2B1 isoforms were 5’ 
TTCGATATGCTTGAGCACTTCCGG 3’ and 5’GCCTCTTCTGCCCCAGGATGT 3’.  
Body weight 
P322S mice were individually housed at 4 (standard chow) or 6 (high fat diet) weeks of age and 
body weight was assessed weekly on the same day of the week and at the same time. DPR mice 
were individually housed at 5 weeks of age and body weight was assessed weekly on the same 
day of the week and at the same time.  Food intake, GTT, ITT, and blood draws for 
determination of hormone levels were performed on these cohorts of mice (see below). 
Food Intake 
Mice were individually housed at week 4 (Fig 1e, 4e) and week 6 (Fig. 2b) and food intake was 
assessed for the weeks indicated (weeks 5-25 for P322S mice fed normal chow; week 27 for 
P322S mice fed a high fat diet; weeks 18-20 for DPR mice). Food was added at the start of each 
week.  At the end of the week, the remaining food was removed and weighed, including that in 
the bedding, and new food was weighed and added for the following week. Bedding was 
changed each week. Nibblers, defined as mice that nibble on the food but do not necessarily eat 
it, were excluded from the study. Food intake for Figures 1e and 4e is shown as cumulative 
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intake meaning that after the first week, new food weight from each week was added to the food 
weight from previous weeks.  
Glucose tolerance tests, insulin tolerance tests, and hormone levels  
For glucose tolerance tests, mice were fasted for 4 hours (9:00 – 13:00), D-glucose (2 g/kg of 
body weight) was injected intraperitoneally, and blood glucose was monitored at 0, 15, 30, 60, 
and 120 minutes after injection. Glucose was assessed using a Bayer contour glucometer and 
glucose strips (part # 7097C). For insulin tolerance tests, mice were fasted for 6 hours (8:00 – 
14:00), human insulin (1 IU/kg of body weight) was injected intraperitoneally and blood glucose 
was monitored at 0, 15, 30, and 60 minutes after injection. To assess insulin levels, mice were 
fasted for 6h (8:00-14:00). Blood was collected in a heparin-coated capillary tube from the tail 
vein of the mice and plasma insulin assessed using an UltraSensitive Mouse Insulin ELISA kit 
(catalog # 90080, Crystal Chem, Inc). To assess leptin levels, blood was either collected between 
9:00- 10:00am from the tail vein of fed mice into heparin-coated capillary tubes (plasma) or at 
euthanasia trunk blood was collected between 10:00 – 13:00 (serum) from fed mice. Leptin was 
assessed using a Mouse Leptin ELISA kit (catalog # 90030, Crystal Chem, Inc). 
Tissue collection 
Mice were euthanized at 12-13 or 31-32 weeks of age using isoflurane followed by decapitation. 
Mice were sacrificed between 10:00 – 13:00. Trunk blood was collected and the serum was 
stored at -80°C for future analysis. Tissues were collected, weighed, snap-frozen in liquid 
nitrogen and stored at -80°C.  
Body composition  
Body composition was measured in 30 week-old mice at room temperature in the morning using 
a Minispec LF90 II Bruker Optics by the University of Michigan Animal Phenotyping Core.  
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Comprehensive Lab Animal Monitoring System (CLAMS) 
For automated metabolic assessment (n= 10-15 per group), animals were first acclimated to 
single housing in home cages for 3 days and then tested in the CLAMS apparatus (Columbus 
Instruments) for 72 hours. O2 consumption (VO2), CO2 production (VCO2), X activity, and Z 
activity were collected in 20-minute bins. The final 24 hours of recordings are presented. 
Subsequent to CLAMS analysis, body composition was measured by nuclear magnetic 
resonance. 
Plasmids 
GFP-tagged rat SH2B1b (GenBank accession number NM_001048180) (8) and SH2B1b P322S 
(92) have been described previously. The DPR deletion was introduced into GFP-SH2B1b using 
the QuikChange II site-directed mutagenesis kit (Stratagene) according to the manufacturer’s 
protocol. Deletion of P317 and R318 was confirmed by Sanger sequencing (University of 
Michigan DNA Sequencing Core). 
Cell culture and transfections 
293T cells (CRL- 3216; AATCC) were maintained at 37°C with humidified air at 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) (11965-092; Life Technologies) supplemented 
with 1 mM L-glutamine, 0.25 µg/ml amphotericin, 100 U/ml penicillin, 100 µg/ml streptomycin 
(DMEM culture medium), and 8% bovine serum (BS; Life Technologies). 293T cells were 
transiently transfected using calcium phosphate precipitation (66). Cells were used after 24 or 48 
hours. PC12 cells (CRL-1721; ATCC) were plated on dishes coated with rat tail type I collagen 
(BD Biosciences) and maintained at 37°C with humidified air at 5% CO2 in in normal growth 
medium (RPMI 1640 medium (A10491-01; Life Technologies) containing 10% horse serum 
(HS; Atlanta Biologicals) and 5% fetal bovine serum (FBS; Life Technologies)). PC12 cells 
 54 
were transiently transfected using Lipofectamine LTX (Life Technologies) for 24 hours 
according to the manufacturer’s instructions.  
Immunoblotting 
Tissues: Tissue lysates were prepared from frozen tissues in L-RIPA lysis buffer (50 mM Tris-
HCl, 150 mM NaCl, 2 mM EGTA, 0.1% Triton X-100, pH 7.2, 1 mM Na3VO4, 1 mM 
phenylmethylsulfonylfluoride [PMSF], 10 µg/ml aprotinin, and 10 µg/ml leupeptin). Protein 
concentration was determined by a DC Protein Assay kit from Bio-Rad Laboratories, Inc. (USA) 
(#500-0112).  Equal amounts of proteins were separated by SDS-PAGE (9% or 7% acrylamide 
gels).  Proteins were then transferred to low-fluorescence PVDF membrane (Bio-Rad; #162-
0264).  Membranes were incubated with monoclonal antibody to SH2B1 (46, Santa Cruz 
Biotechnology; Cat #sc-136065, RRID:AB_2301871) or b-tubulin (G-8, Santa Cruz 
Biotechnology; Cat #sc-55529, RRID:AB_2210962) in 10 mM Tris, 150 mM NaCl, pH 7.4, 
0.1% Tween 20, 3% BSA overnight at 4 °C with constant rocking followed by incubation with 
IRDye-conjugated mouse secondary antibody was added (1:20,000 dilution) for 1 hour at room 
temperature.  Protein signal was detected using the Odyssey infrared imaging system (Li-Cor 
Biosciences). For immunoprecipitations, cell lysates containing equal amounts of protein were 
incubated with monoclonal antibody 46 to SH2B1 (1:100) (Santa Cruz Biotechnology; Cat #sc-
136065, RRID:AB_2301871) at 4 °C overnight followed by incubation with protein A-agarose 
beads (RepliGen; #7489) at  4 °C for 1 hour.  Samples were centrifuged at 3000 x g at 4 °C for 1 
minute.  The beads were washed three times with L-RIPA lysis buffer.  Samples were 
resuspended in 62.5 mM Tris/HCl (pH 6.8), 2% (w/v) SDS, 0.05% (w/v) bromophenol blue, 
10% (v/v) glycerol, and 5% (v/v) β-mercaptoethanol and boiled at 95 °C for 10 minutes.   
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PC12 cells: Cells were seeded at ~40-50% confluency per 10-cm collagen-coated dish in normal 
growth medium. Cells were then transfected either the same day or the next day. 24 hours after 
transfection, cells were incubated overnight in RPMI 1640 medium with 2% horse serum and 1% 
fetal bovine serum (deprivation medium). Cells were incubated at 37°C with 25 ng/ml NGF 
(Harlan Envigo; BT.5025) as indicated, placed on ice, and washed two times with phosphate-
buffered saline (PBS; 10 mM NaPO4, 140 mM NaCl, pH 7.4) containing 1 mM Na3VO4, pH 7.3 
(PBSV). Cells were lysed with boiling L-RIPA lysis buffer supplemented with 20 mM NaF in 
Laemmli loading buffer for 10 min on ice. Whole cell lysates were centrifuged at 15,000 x g for 
10 min at 4°C, and proteins were resolved using 9% SDS-PAGE gels and transferred to low-
fluorescence PVDF (Bio-Rad) membranes. Blots were incubated overnight at 4°C with 
antibodies in 10 mM Tris, 150 mM NaCl, pH 7.4, 0.1% Tween 20, 3% BSA followed by 
secondary antibody for 1 hour at room temperature. Bands were visualized using the Odyssey 
infrared imaging system (Li-Cor Biosciences). 
Neurite outgrowth 
PC12 cells were plated in 6-well dishes and transiently transfected with the indicated construct. 
Cells were incubated overnight in deprivation medium and then treated with 25 ng/ml mouse 
NGF. After 2 days, GFP-positive cells were visualized by fluorescence microscopy (40X 
objective, Nikon Eclipse TE200). One hundred GFP-positive cells in three different areas of each 
plate were scored for the presence of neurites 2 times the length of the cell body (total of 300 
cells per condition per experiment). Each experiment was carried out 3 times. The percentage of 
GFP-positive cells with neurites was determined by dividing the number of GFP-positive cells 
with neurites by the total number of GFP-positive cells counted. 
Live cell imaging 
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GFP, GFP-tagged SH2B1, or GFP-tagged SH2B DPR mutant was transiently expressed in 293T 
cells or PC12 cells seeded on 35-mm glass-bottom dishes (MatTek) in normal growth medium. 
Cells were imaged in normal growth medium using a 60X water immersion objective on an 
Olympus FV500 laser-scanning confocal microscope and FluoView version 5.0 software 
(Morphology and Image Analysis Core of the Michigan Diabetes Research Center). A multiline 
argon blue laser was used to excite GFP fluorescence at 488 nm. For each condition, 18 to 30 
cells were counted. Dying or dead cells and cells with a particularly high or low expression level 
were excluded (usually ~10% of the cells). 
Structural modeling and ClustalW analysis 
The structural modeling of the PH domain of SH2B1 was based on the NMR structure of 
SH2B2/APS (1V5M) (reference Li H) as visualized using the PyMOL Molecular Graphics 
System, version 2.2.3) (http://www.pymol.org).  The numbering of the residues in the 
SH2B2/APS structure are offset from the numbering in SH2B2 (translated from NM_020979.1) 
(eg., the first residue in the PH domain of APS (Q19) is Q195 in human SH2B2.)  Residue 
numbering with 2 digits refers to the numbering in the APS structure.  ClustalW alignments were 
performed using LaserGene, version 14.0.0 (DNASTAR, Madison, WI).  Functional homology 
was determined using the PAM250 mutation probability matrix.  Functional homology was 
defined as residues that match the consensus within 1 distance unit using the PAM250 mutation 
probability matrix. 
Statistics  
All analyses were carried out using GraphPad Prism software. Body weight, glucose tolerance 
tests, and insulin tolerance tests were analyzed by 2-way ANOVA followed by Fisher’s Least 
Significant Difference post-test. Food intake curves for P322S mice on standard chow and DPR 
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mice were analyzed by linear regression. For other physiological parameters, experimental 
animals were independently compared with their WT littermates by two-tailed Student’s t test. 
Survival phenotype for P322S or DPR mice was analyzed by a Chi-square test. Neurite 
outgrowth was analyzed by a two-tailed Student’s t test. For all comparisons, *P <0.05 was 
considered significant. 
 
Note: The work described in this chapter, in modified form, will be submitted for publication 
under the title “Crucial Role of SH2B1 PH Domain Function for the Control of Energy Balance 
and Metabolism” by Anabel Flores, Lawrence S. Argetsinger, Alvaro Malaga, Paul Vander, 
Lauren C. DeSantis, Ray M. Joe, Gowri Chandrashekar, Joel C. Cline, Erik Clutter, Yixin Hu, 
Jeanne Stuckey, Martin G. Myers Jr., Christin Carter-Su. A.F., (with the help of) L.S.A., 
M.G.M., and C.C-S. developed the concept, designed experiments, interpreted the data, helped 
direct experiments, conducted most experiments, analyzed the data, and prepared the manuscript. 
A.M., L.D., G.C., and Y.H. helped measure body weight and food intake (Figures 2.1d-e, 2.2a-b, 
2.4d-e).  A.M. helped re-genotype the mice. P.V. conducted neurite outgrowth experiments 
(Figure 2.8d) and helped with experiments for Figure 2.8a and c. R.M.J. conducted preliminary 
experiments for Figure 2.8b. E.S.C. maintained mouse colonies and helped collect blood samples 
(Figures 2.12c and 2.14a). J.M.C. made the GFP-SH2B1 WT and GFP-SH2B1 DPR constructs 
(Figure 2.8).  J.S. and L.S.A. analyzed the model of the PH domain (Figure 2.18).  
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Figure 2.1 The effect of the P322S mutation in SH2B1 on body weight, food intake, body 
composition and glucose metabolism of mice fed standard chow. 
a) Sh2b1 gene structure and position of primers used to assess isoform-specific mRNAs.  Exons 
are noted by numerals.  Stop codons for each isoform are noted. b) CRISPR-cas9 schematic for 
SH2B1 P322S gene editing.  Shown are the RNA sequence of guide 2, PAM sequence for this 
guide, cut site for Cas9, the sequence of the 180 nt oligo donor template directing homology-
directed repair in the region of the cut site, and the sequence of Sh2b1 in the regions of the codon 
for both P322 and the DP317, R318 deletion. Mutations in the donor template that introduce the 
C>T mutation to code for P322S and silent mutations to create a diagnostic XbaI site and disrupt 
guide RNA binding following repair are highlighted in red.  c) Proteins in brain tissue lysates 
from WT, P322S/P322S, and KO male mice were immunoblotted with αSH2B1 or αb-tubulin.  
Migration of the 100 kDa protein standard and the four known isoforms of SH2B1 are shown. d) 
Body weight was assessed at weeks 4-29. Means ±SEM. Males: n=8 (WT), 16 (P322S/+), 4 
(P322S/P322S).  Females n=10 (WT), 14 (P322S/+), 3 (P322S/P322S).  e) Food intake was 
assessed at weeks 5-25.  Means ± SEM. Males n=7 (WT), 8 (P322S/+).  Females n=7 (WT), 9 
(P322S/+).  f) Body fat mass was determined at week 30.  Percent fat mass was determined by 
dividing fat mass by body weight. Means ± SEM.  Males: n=9 (WT), 16 (P322S/+); females: 
n=14 (WT, P322S/+). g) GTT was assessed at 28 weeks. After a 4-hour fast, mice were injected 
intraperitoneally with D-glucose (2 mg/kg of body weight).  Blood glucose was monitored at 
indicated times. Means ± SEM.  Males: n=8 (WT), 14 (P322S/+).  Females: n=9 (WT), 14 
(P322S/+).  h) ITT was assessed at 29 weeks. After a 6-hour fast, mice were injected 
intraperitoneally with insulin (1 IU/kg of body weight).  Blood glucose was monitored at 
indicated times.  Means ± SEM.  Males: n=8 (WT), 15 (P322S/+).  Females: n=9 (WT), 13 
(P322S/+).  i) 13-week-old male mice were fasted overnight and insulin levels were determined. 
Means ± SEM, n=5. 
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Figure 2.2 The P322S mutation does not affect mRNA or protein levels of the 4 known 
isoforms of SH2B1. 
a) Sequencing of DNA from mice from the N1 generation confirms germline transmission of the 
SH2B1 P322S mutation.  The relevant region of DNA sequence from one of the P322S/+ mice 
and a WT littermate are shown.  The codons for P322 (upper panel) and S322 (lower panel) are 
underlined.  The peaks corresponding to the C >T mutation are denoted by asterisks. b) mRNA 
was extracted from brain, liver, and heart tissue of SH2B1 WT, P322S/+, and P322S/P322S male 
mice.  A ladder of DNA standards and isoform-specific PCR products are shown on the left and 
right, respectively. Location of forward and reverse primers are shown in Fig. 1a. c) Proteins in 
lysates from brain tissues from WT, P322S/P322S and KO mice were immunoprecipitated and 
immunoblotted with αSH2B1.  The migration of the 100 kDa protein standard and four known 
isoforms of SH2B1 are shown on the left and right, respectively. d) P322S/P322S mice from 
intercrosses of heterozygous mice are born at approximately half (1 out of 7) of the expected (1 
out of 4) Mendelian ratio. n = 179 mice. Chi-Square Test, *P<0.05. 
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Figure 2.3 The P322S mutation does not affect lean body mass of mice fed standard chow. 
a) Lean body mass was determined using NMR at week 30. Percent lean mass was determined 
by dividing fat mass by body weight. Means ± SEM.  Males: n=9 (WT), 16 (P322S/+); females: 
n=14.  b) At week 30, serum from P322S/+ and control male mice was assayed for leptin.  
Means ± SEM. n=5 (WT), 8 (P322S/+).  
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Table 2.1 Weight of organs in SH2B1 P322S/+ mice fed standard chow 
 
Males WT (n=8) P322S/+ (n=13) Females WT (n=10) P322S/+ (n=13)
brain 0.45 ± 0.02 g 0.46 ± 0.01 g brain 0.47 ± 0.01 g 0.47 ± 0.01 g
heart 0.18 ± 0.01 g 0.18 ± 0.01 g heart 0.17 ± 0.01 g 0.16 ± 0.01 g
kidney 0.23 ± 0.01 g 0.21 ± 0.01 g kidney 0.16 ± 0.01 g 0.16 ± 0.01 g
perigonadal fat 2.06 ± 0.19 g 1.49 ± 0.14 g perigonadal fat 0.83 ± 0.18 g 0.68 ± 0.15 g
testis 0.10 ± 0.01 g 0.12 ± 0.01 g
Table 2.1 Weight of organs is similar at week 32-33 in SH2B1 P322S/+ mice and their WT littermates fed 
standard chow. Means ±SEM are shown. 
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Figure 2.4 The P322S mutation does not affect glucose tolerance or insulin sensitivity in 
mice fed standard chow. 
a) 28-week-old mice were fasted for 4 hours and blood glucose was measured. b) GTT was 
assessed at 28 weeks.  Mice fed standard chow were fasted for 4 hours and then injected 
intraperitoneally with D-glucose (2 mg/kg of body weight).  Blood glucose was monitored (see 
Fig. 1g) and the area under the curve (AUC) was calculated. Means ± SEM. Males: n=8 (WT), 
14 (P322S/+).  Females: n=9 (WT), 14 (P322S/+).  c) ITT was assessed at 29 weeks.  Mice were 
fasted for 6 hours then injected intraperitoneally with human insulin (1 IU/kg of body weight).  
Blood glucose was monitored (see Fig. 1h) and the area under the curve (AUC) was calculated. 
Means ± SEM are shown. Males: n=8 (WT), 15 (P322S/+).  Females: n=9 (WT), 13 (P322S/+). 
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Figure 2.5 The P322S mutation in SH2B1 leads to impaired glucose homeostasis in mice 
challenged with a high fat diet. 
a) Starting at week 6, body weight was assessed weekly.  Means ±SEM.  Males: n=7 (WT), 12 
(P322S/+).  Females: n=9 (WT), 20 (P322S/+).  b) Food intake was measured during week 27.  
Means ± SEM are shown.  Males: n=7 (WT), 12 (P322S/+). Females: n=5 (WT), 14 (P322S/+). 
c) GTT was assessed at 28 weeks.  Mice were fasted for 4 hours and then injected 
intraperitoneally with D-glucose (2 mg/kg of body weight).  Blood glucose was monitored at 
times indicated.  Means ± SEM. Males: n=7 (WT), 12 (P322S/+).  Females: n=9 (WT), 20 
(P322S/+).  d) ITT was assessed at 29 weeks-old. Mice were fasted for 6 hours and then injected 
intraperitoneally with human insulin (1 IU/kg of body weight). Blood glucose was monitored at 
the times indicated.  Means ± SEM.  Males: n=6 (WT), 10 (P322S/+).  Females: n=9 (WT), 20 
(P322S/+).  e) At week 30, mice were fasted overnight and insulin levels were determined.  
Means ± SEM.  Males: n=6 (WT), 7 (P322S/+).  Females: n=8 (WT, P322S/+). f) Body fat mass 
was determined at week 30.  Means ± SEM.  Males: n=7 (WT), 11 (P322S/+).  Females: n=9 
(WT), 20 (P322S/+). For all comparisons: * P<0.05, **P<0.01. 
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Figure 2.6 The P322S mutation in SH2B1 leads to impaired glucose homeostasis in mice 
challenged with a high fat diet. 
a) 29-week-old mice were fasted for 6 hours and blood glucose was measured. Means ± SEM. 
Males: n=6 (WT), 10 (P322S/+).  Females: n=9 (WT), 20 (P322S/+). b) GTT was assessed at 28 
weeks.  Mice were fasted for 4 hours and then injected intraperitoneally with D-glucose (2 mg/kg 
of body weight).  Blood glucose was monitored (see Fig. 2d) and the area under the curve (AUC) 
was calculated.  Means ± SEM. Males: n=7 (WT), 12 (P322S/+).  Females: n=9 (WT), 20 
(P322S/+).  c) ITT was assessed at 29 weeks.  Mice were fasted for 6 hours and then injected 
intraperitoneally with human insulin (1 IU/kg of body weight). Blood glucose was monitored 
(see Fig. 2e) and the area under the curve (AUC) was calculated.  Means ± SEM. Males: n=6 
(WT), 10 (P322S/+).  Females: n=9 (WT), 20 (P322S/+). For all comparisons: *P<0.05 and 
**P<0.01 when compared to WT littermates. 
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Figure 2.7 The P322S mutation does not affect lean mass in mice fed a high fat diet. 
a) Lean body mass of mice fed a high fat diet (cohort used in Fig. 2) was determined at week 30.  
Percent lean mass was determined by dividing fat mass by body weight. Means ± SEM.  Males: 
n=7 (WT), 11 (P322S/+).  Females: n=9 (WT), 20 (P322S/+). 
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Table 2.2 Weight of organs in SH2B1 P322S/+ mice fed a high fat diet.  
 
 
 
 
 
 
Males WT (n=7) P322S/+ (n=11) Females WT (n=9) P322S/+ (n=20)
brain 0.45 ± 0.01 g 0.46 ± 0.004 g brain 0.47 ± 0.01 g 0.47 ± 0.00 g
heart 0.22 ± 0.02 g 0.19 ± 0.01 g heart 0.17 ± 0.01 g 0.17 ± 0.00 g
kidney 0.24 ± 0.02 g 0.23 ± 0.01 g kidney 0.18 ± 0.01 g 0.19 ± 0.01 g
perigonadal fat 1.47 ± 0.16 g 1.21 ± 0.11 g perigonadal fat 3.27 ± 0.32 g 3.63 ± 0.11 g
testis 0.10 ± 0.01 g 0.11 ± 0.01 g
Table 2.2 Weight of organs is similar at week 32-33 in SH2B1 P322S/+ mice and their WT littermates fed a 
high fat diet. Means ±SEM are shown.
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Figure 2.8 Disruption of the PH domain changes the subcellular localization of SH2B1 and 
impairs the ability of SH2B1 to enhance NGF-induced neurite outgrowth. 
a) Proteins in whole cell lysates from PC12 cells transiently expressing the indicated GFP-
SH2B1b mutants were immunoblotted with αSH2B1. Migration of molecular weight standards 
are on the left. b) and c) Live 293T cells (b) and PC12 cells (c) transiently expressing the 
indicated GFP-SH2B1b WT or GFP-SH2B1bDPR were imaged by confocal microscopy. d) Live 
PC12 cells transiently expressing GFP-SH2B1b WT or GFP-SH2B1bDPR were treated with 25 
ng/ml mouse NGF for 2 days after which neurite outgrowth was assessed. GFP-positive cells 
were scored for the presence of neurites 2 times the length of the cell body (total of 300 cells per 
condition per experiment). The percentage of cells with neurites was determined by dividing the 
number of GFP-positive cells with neurites by the total number of GFP-positive cells. Means ± 
SEM, *P<0.05, n=3.  
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Figure 2.9 Sequencing of mice from the N1 generation confirms germline transmission of 
the SH2B1 ΔPR (P317, R318) mutation.   
a) The relevant DNA sequence from one of the ΔPR/ΔPR mice and a WT littermate are shown.  
The codons for P317, R318 are underlined in blue.  The missing codons for P317, R318 in the 
Sh2b1 ΔPR/ΔPR mice are shown by an arrow. b) The ΔPR mice are born at the expected (1 out of 
4) Mendelian ratio. n = 183 mice. 
WT
ΔPR Deletion
a. b.
ΔPR/ΔPR
 29%
WT
26%
ΔPR/+
45%
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Figure 2.10 Disruption of the PH domain in SH2B1 results in obesity. 
a) mRNA was extracted from brain and heart tissue of WT and DPR/DPR male mice.  The 
migration of a ladder of DNA standards and isoform-specific PCR products are shown on the left 
and right, respectively. b) Proteins in brain lysates from SH2B1 WT, DPR/DPR, and KO male 
mice were immunoblotted with αSH2B1 and αb-tubulin.  The migration of the 100 kDa protein 
standard and the four known isoforms of SH2B1 or b-tubulin are shown on the left and right, 
respectively. c) Representative male WT and DPR/DPR mice (6 months). d) Perigonadal fat of 
representative male wild-type littermate and DPR/DPR mouse (6 months). e) Body weight was 
assessed weekly starting at week 5.  Means ±SEM.  Males: n= 9 (WT, DPR/DPR), 14 (DPR/+).  
Females: n=7 (WT), 16 (DPR/+), 11 (DPR/DPR).  f) Food intake was measured between weeks 
17-20.  Means ± SEM.  Males: n= 11 (WT), 10 (DPR/+), 7 (DPR/DPR). Females: n=6 (WT), 9 
(DPR/+, DPR/DPR). g)  Oxygen consumption was assessed at 11-12 weeks using CLAMS.  VO2 
normalized to lean body mass (LBM). For all comparisons: * P<0.05. 
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Figure 2.11 Energy expenditure and locomotor activity in DPR mice. 
Energy expenditure and locomotor activity were assessed at 11-12 weeks using CLAMS.  a) 
Respiratory exchange ratio (RER) (VCO2/VO2). b) Horizontal activity. c) Vertical (rearing) 
activity. Means ± SEM. Males: n=13 (WT), 10 (DPR/+), 11 (DPR/DPR). Females: n=11 (WT), 
15 (DPR/+), 13 (DPR/DPR).  For all comparisons:  *P<0.05 when compared to WT littermates.  
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Figure 2.12 Disruption of the PH domain in SH2B1 results in increased adiposity. 
a, b) Body fat and lean mass was determined at weeks 24-26. Percent fat or lean mass was 
determined by dividing fat mass by body weight.  Means ± SEM.  Males: n=5 (WT, PR/+, 
DPR/DPR). Females: n= 5 (WT), 11 (DPR/+), 8 (DPR/DPR). c) At week 24-26, serum from WT,  
DPR/+, and DPR/DPR male and female mice was assayed for leptin. Means ± SEM. Males: n= 8 
(WT, PR/+, PR/DPR). Females: n=7 (WT), 6 (DPR/+), 9 (DPR/DPR). For all comparisons: * 
P<0.05, **P<0.01, and ***P<0.001.  
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Figure 2.13 Disruption of the PH domain in SH2B1 results in increased adiposity in young 
male mice. 
a, b) Body fat and lean mass was determined at weeks 24-26.  Means ± SEM.  Males: n=5 (WT, 
PR/+, DPR/DPR). Females: n= 5 (WT), 11 (DPR/+), 8 (DPR/DPR). c) Body fat and (d) lean mass 
were determined at week 11-12. Means ± SEM.  Males: n=13 (WT), 10 (DPR/+), 11 (DPR/DPR). 
Females: n=11 (WT), 15 (DPR/+), 13 (DPR/DPR). For all comparisons: * P<0.05 and **P<0.01. 
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Figure 2.14 Adiposity correlates with increased leptin levels in SH2B1 ΔPR mice. 
a) At week 7, serum from WT, DPR/+, and DPR/DPR male mice was assayed for leptin.  Means 
± SEM.  Males: n=8 (WT, DPR/DPR), 7 (DPR/+). Females: n=8 (WT), 5 (DPR/+), 12 
(DPR/DPR). b) Body fat and (c) lean mass were determined at week 11-12. Percent fat or lean 
mass was determined by dividing the mass by body weight.  Means ± SEM.  Males: n=13 (WT), 
10 (DPR/+), 11 (DPR/DPR). Females: n=11 (WT), 15 (DPR/+), 13 (DPR/DPR). For all 
comparisons: * P<0.05 and **P<0.01. 
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Table 2.3 Weight of organs from 26-27-week-old DPR mice. 
 
 
Males WT (n=8) ΔPR/+ (n=15) ΔPR/ΔPR (n=10)
brain 0.46 ± 0.01 g 0.46 ± 0.01 g 0.44 ± 0.00 g
heart 0.14 ± 0.01 g 0.15 ± 0.00 g 0.16 ± 0.01 g
liver 1.48 ± 0.05 g 1.51 ± 0.06 g 2.96 ± 0.19 g ****
perigonadal fat 1.42 ± 0.21 g 1.97 ± 0.14 g * 2.12 ± 0.13 g *
inguinal fat 0.82 ± 0.12 g 1.13 ± 0.08 g * 1.82 ± 0.09 g ****
brown fat 0.11 ± .01 g 0.15 ± .02 g 0.19 ± 0.01 g ***
Females WT (n=7) ΔPR/+ (n=15) ΔPR/ΔPR (n=11)
brain 0.46 ± 0.01 g 0.46 ± 0.00 g 0.45 ± 0.00 g
heart 0.13 ± 0.02 g 0.13 ± 0.00 g 0.13 ± 0.01 g
liver 1.14 ± 0.06 g 1.20 ± 0.04 g 1.14 ± 0.12 g
perigonadal fat 0.52 ± 0.09 g 0.84 ± 0.16 g 1.96 ± 0.35 g **
inguinal fat 0.43 ± 0.07 g 0.60 ± 0.09 g 1.36 ± 0.25 g **
brown fat 0.08 ± 0.01 g 0.08 ± 0.01 g 0.14 ± 0.03 g
Table 2.3 Weight of organs at week 26-27 in Sh2b1ΔPR/ +,Sh2b1ΔPR/ ΔPR mice and 
their WT littermates fed standard chow. Means ±SEM are shown. *P< 0.05, 
**P<0.01, ***P<0.001 and ****P<0.0001 when compared to wild-type littermates. 
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Table 2.4 Weight of organs from 12-14-week-old DPR mice. 
 
Males WT (n=10) ΔPR/+ (n=10) ΔPR/ΔPR (n=7)
brain 0.46 ± 0.00 g 0.45 ± 0.00 g 0.45 ± 0.00 g
liver 1.22 ± 0.04 g 1.28 ± 0.08 g 1.37 ± 0.10 g
perigonadal fat 0.50 ± 0.03 g 0.54 ± 0.04 g 1.06 ± 0.18 g *
Females WT (n=11) ΔPR/+ (n=14) ΔPR/ΔPR (n=12)
brain 0.46 ± 0.00 g 0.45 ± 0.00 g 0.45 ± 0.00 g
liver 0.97 ± 0.03 g 0.99 ± 0.05 g 1.06 ± 0.03 g *
perigonadal fat 0.19 ± 0.02 g 0.30 ± 0.07 g 0.44 ± 0.11 g *
Table 2.4 Weight of organs at week 12-14 in Sh2b1ΔPR/ +,Sh2b1ΔPR/ ΔPR mice and 
their WT littermates fed standard chow. Means ±SEM are shown. * p < 0.05 
when compared to wild-type littermates. 
 81 
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Figure 2.15 SH2B1 DPR mice exhibit reduced glucose tolerance and insulin sensitivity. 
a) GTT was assessed at 18 weeks. Mice were fasted for 4 hours and then injected 
intraperitoneally with D-glucose (2 mg/kg of body weight). Blood glucose was monitored at 
times indicated.  Means ± SEM.  Males: n= 8 (WT), 12 (DPR/+), 10 (DPR/DPR). Females: n=7 
(WT), 14 (DPR/+), 10 (DPR/DPR). b) ITT was assessed at 19 weeks. Mice were fasted for 6 
hours and then injected intraperitoneally with human insulin (1 IU/kg of body weight). Blood 
glucose was monitored at the times indicated.  Means ± SEM.  Males: n= 9 (WT), 14 (DPR/+), 
11 (DPR/DPR). Females: n=6 (WT), 13 (DPR/+), 11 (DPR/DPR).  c) In a separate study, GTT 
was assessed at 8 weeks. Mice were fasted for 4 hours and then injected intraperitoneally with D-
glucose (2 mg/kg of body weight). Blood glucose was monitored at the times indicated.  Means ± 
SEM. Males: n= 13 (WT), 10 (DPR/+), 11 (DPR/DPR). Females: n=10 (WT), 13 (DPR/+), 12 
(DPR/DPR). d) 9-week-old mice were fasted for 6 hours and then injected intraperitoneally with 
human insulin (1 IU/kg of body weight). Blood glucose was monitored at the times indicated.  
Means ± SEM.  Males: n=11 (WT), 9 (DPR/+), 10 (DPR/DPR). Females: n=9 (WT), 11 (DPR/+), 
13 (DPR/DPR). e) 8-week-old mice were fasted for 6 hours and insulin levels were determined.  
Means ± SEM. Males: n=11 (WT), 9 (DPR/+), 10 (DPR/DPR). Females: n=9 (WT), 11 (DPR/+), 
13 (DPR/DPR). For all comparisons: * P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 when 
compared to WT littermates.  
 
 83 
 
 
 
 
 
 
a.
b.

	




 






!






	"

  


	




 !






"
 





 	# 

  
 

	




"%"





$
!"

&

 
$#
"




  

	









$
!"

&

 
$#
"

 "%"
  
 "

c.






	
 $	'$


!

 
&
#$

(
!
"
&%
$



  
"$

	







 


%
"#

'
 
!
%$
#

  #&#
  
!#
!#
 84 
Figure 2.16 DPR mice exhibit reduced glucose tolerance and insulin sensitivity. 
a) At week 18, mice were fasted for 4 hours and blood glucose was measured. Means ± SEM. 
Males: n= 8 (WT), 12 (DPR/+), 10 (DPR/DPR). Females: n=7 (WT), 14 (DPR/+), 10 (DPR/DPR).  
b) GTT was assessed at 18 weeks.  Mice were fasted for 4 hours and then injected 
intraperitoneally with D-glucose (2 mg/kg of body weight). Blood glucose was monitored at the 
times indicated (see Fig. 7a) and the area under the curve (AUC) was calculated. Means ± SEM. 
Males: n= 8 (WT), 12 (DPR/+), 10 (DPR/DPR). Females: n=7 (WT), 14 (DPR/+), 10 (DPR/DPR). 
c) ITT was assessed at 19 weeks. Mice were fasted for 6 hours and then injected intraperitoneally 
with human insulin (1 IU/kg of body weight). Blood glucose was monitored at the times 
indicated (see Fig. 7b) and the area under the curve (AUC) was calculated.  Means ± SEM. 
Males: n=9 (WT), 14 (DPR/+), 11 (DPR/DPR). Females: n=6 (WT), 13 (DPR/+), 11 (DPR/DPR). 
For all comparisons: **P<0.01, ***P<0.001, and ****P<0.0001 when compared to WT 
littermates. 
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Figure 2.17 DPR mice exhibit reduced glucose tolerance prior to the onset of obesity. 
a) At week 18, mice were fasted for 4 hours and blood glucose was measured. Means ± SEM. 
Males: n=13 (WT), 10 (DPR/+), 11 (DPR/DPR).  Females: n=10 (WT), 13 (DPR/+), 12 
(DPR/DPR). b) GTT was assessed at 8 weeks.  Mice were fasted for 4 hours and then injected 
intraperitoneally with D-glucose (2 mg/kg of body weight). Blood glucose was monitored at 
times indicated (see Fig. 7c) and the area under the curve (AUC) was calculated.  Means ± SEM. 
Males: n=13 (WT), 10 (DPR/+), 11 (DPR/DPR).  Females: n=10 (WT), 13 (DPR/+), 12 
(DPR/DPR). c) ITT was assessed at 9 weeks. Mice were fasted for 6 h and then injected 
intraperitoneally with human insulin (1 IU/kg of body weight). Blood glucose was monitored at 
the times indicated (see Fig. 7d) and the area under the curve (AUC) was calculated.  Means ± 
SEM. Males: n=11 (WT), 9 (DPR/+), 10 (DPR/DPR). Females: n=9 (WT), 11 (DPR/+), 13 
(DPR/DPR). For all comparisons: **P<0.01 and ***P<0.001 when compared to WT littermates. 
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Figure 2.18 Modeling and analysis of the 3-D structure of the PH domain of SH2B1 in the 
region of P317, R318, and P322. 
a. ClustalW of SH2B1, SH2B2/APS, and SH2B3/Lnk.  The region included in the NMR 
structure of APS (1V5M) is shown.  Homologous residues are highlighted in black, functionally 
homologous residues are cyan.  The PH domain is indicated by the blue line above the 
sequences.  Locations of the human mutations in SH2B1 associated with obesity and P317, R318 
in SH2B1 are indicated in magenta.  The mutations in Lnk associated with myeloproliferative 
neoplasms are indicated in blue boxes.  Residues within 6Å of P71 in APS (P317 in SH2B1, 
P240 in SH2B3/Lnk) are denoted by a blue double rectangle.  Residues within 6Å of K72 in APS 
(R318 in SH2B1, K241 in SH2B3/Lnk) are denoted by a light green double rectangle.  Residues 
within 6Å of P76 (P322 in SH2B1, P245 in SH2B3/Lnk) are denoted by a green double 
rectangle.  b-c.  Residues in SH2B2/APS that correspond to human mutations in SH2B1 and 
residues P317, R318 in SH2B1 are magenta.  Residues corresponding to human mutations in Lnk 
are grey.  Residues that are homologous or functionally homologous in human SH2B1 and 
SH2B2/APS are denoted by green lines.  The non-homologous residues are denoted by orange 
sticks.  Oxygen atoms are red, nitrogen blue, sulfur orange, hydrogen grey.  b-pleated sheets, a-
helices, and connecting loops are indicated.  b.  Region in the APS structure in the vicinity of 
P71 and K72 (P317, R318 in SH2B1) and P76 (P322 in SH2B1).  The exterior surface of the PH 
domain is tinted grey.  c.  Region in the APS structure in the vicinity of P71 and K72 (P317, 
R318 in SH2B1), F63 (F309 in SH2B1; F240 in Lnk), and C45 and L48 (sites of the human 
mutations G220V, G220R and A223V in Lnk).  Compared to the image in b), the image in c) is 
rotated ~90o counter-clockwise and ~90o back.  d.  Region in the APS structure in the vicinity of 
P76 (P322 in SH2B1), R57 and A52 (sites of the human mutations D234N and G229S in Lnk), 
and V53 (the site of the human E299G mutation in SH2B1).   
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Chapter 3  
Conclusions and Future Directions 
 The overall goal of my thesis research was to elucidate the contribution of the PH domain 
to SH2B1 regulation of energy balance and glucose homeostasis. One approach took advantage 
of the human mutations identified in patients with severe obesity, insulin resistance, and 
maladaptive behavior. The second approach introduced a two-amino acid deletion in the PH 
domain of SH2B1. Both approaches took advantage of CRISPR/Cas9 genome editing in mice to 
disrupt the PH domain of SH2B1, by introducing either a point mutation associated with human 
obesity P322S or the 2-amino acid deletion of P317 and R318 (ΔPR).  
Regarding the first approach of introducing the PH domain-located P322S point mutation 
into SH2B1 in mice, we show that the P322S human obesity-associated mutation does not affect 
body weight, food intake or insulin sensitivity of heterozygote mice.  Studies using a smaller 
cohort (3-4 animals) of homozygote mice fed a standard chow gave similar results. Although the 
P322S mutation in SH2B1 in mice also did not seem to affect glucose tolerance or insulin 
sensitivity under standard chow conditions, the P322S mutation did decrease glucose tolerance 
when the mice were challenged with a high fat diet. Since glucose tolerance, but not insulin 
tolerance, was reduced on a high fat diet, future experiments should test whether the P322S mice 
have impaired insulin secretion from b-cells. In order to help address this possibility, insulin 
concentrations should be measured during a glucose tolerance test to assess if the b-cells have 
the same or decreased ability to secrete insulin into the blood compared to WT mice.  An 
additional experiment to address if P322S mice have impaired insulin secretion from b-cells is to 
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isolate islets from the mice and measure insulin content, insulin secretion from islets in the 
presence of glucose, and levels of insulin mRNA. It is also possible that the P322S mice may 
have reduced insulin tolerance and that the insulin tolerance test is not sensitive enough to detect 
this. A more sensitive test to check the insulin tolerance in the P322S mice would be the use of 
hyperinsulinemic-euglycemic clamps.  
Our findings suggest that, in mice, the P322S mutation does not replicate the full 
spectrum of effects seen in humans with the SH2B1 P322S mutation.  Because environmental 
factors such as diet, exercise and other behavioral patterns greatly increase the prevalence of 
obesity in a population (181), it is possible that other environmental conditions or genetic 
backgrounds may reveal a phenotype in mice with the SH2B1 P322S mutation that more closely 
resembles the obese, insulin-resistant phenotype ascribed to humans with the P322S mutation. 
To further investigate whether one of these alternative factors (e.g. a diet high in fructose) may 
work in concert with the P322S mutation to cause obesity, I challenged P322S mice with a 70% 
high fructose diet. The P322S mice did not exhibit obesity compared to their WT littermates 
(Figure 3.1), suggesting that there may be other factors contributing to the penetrance of the 
pathogenicity of the P322S mutation in humans.  The impact of genetic background could also 
be tested using breeding or CRISPR/Cas9 to introduce the P322S mutation into another breed of 
mice or using CRISPR/Cas9 to introduce the P322S mutation into another animal species. The 
finding that the P322S homozygous mice are born at lower frequencies than the homozygous 
ΔPR mice raises the possibility that the ability of SH2B1 to enter the nucleus, as seen with the 
P322S mutation (92) and not with the ΔPR mutation (shown here), affects the function of SH2B1 
in the implantation/development of the pups.  
In contrast to the P322S mutation, the relatively small deletion in the PH domain present  
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Figure 3.1 The P322S mutation does not affect body weight of mice fed a high fructose diet.  
Starting at week 5, body weight was assessed weekly.  Means ±SEM.  Males: n=10 (WT), 16 
(P322S/+), 12 (P322S/P322S).  Females: n=9 (WT), 16 (P322S/+), 12 (P322S/P322S).   
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in ΔPR, causes a rather profound effect on both SH2B1b localization at the cellular level and 
energy balance and glucose homeostasis at the whole animal level.  This is despite the fact it is 
predicted to have only a minor effect on the structure of the PH domain based on PH domain 
modeling using NMR structure data for the PH domain of family member SH2B2, The ΔPR 
mice show increased body weight, adiposity, food intake, and reduced glucose tolerance and 
insulin sensitivity. At the cellular level, the ΔPR mutation alters the subcellular localization of 
SH2B1 and impairs the ability of SH2B1 to enhance NGF-induced neurite outgrowth in PC12 
cells. It is still not clear if the DPR deletion affects the subcellular localization of other isoforms 
of SH2B1. In preliminary experiments, I found that SH2B1d DPR localized to nuclear bodies in 
PC12 cells (Figure 3.2a), in addition to localizing in the nucleus, nucleolus, and plasma 
membrane as is seen with SH2B1d WT.  SH2B1 enhancement of NGF-induced neuronal 
differentiation of PC12 cells was also impaired, as was found when the DPR mutation was 
introduced into SH2B1b (Figure 3.2b). I am in the process of testing if the DPR deletion also 
affects the subcellular localization of the a and g isoforms of SH2B1.  
The neuronal assays utilized here focused on the effect of SH2B1 on NGF signaling in 
PC12 cells. However, SH2B1 has also been shown to interact with the activated receptors for 
BDNF (TrkB) and GDNF (RET) (182), interactions that are likely to be more relevant than the 
SH2B1 effects on NGF signaling in regards to energy balance. Investigating the effect of the PH 
domain mutations of SH2B1 in BDNF signaling is particularly relevant for these studies because 
genetic variations that cause reduced BDNF or TrkB expression or activity lead to hyperphagia 
and obesity in humans and mice (110). A role for SH2B1 in neuronal development, architecture 
and/or neuronal signaling using BDNF and GDNF in cortical and hippocampal neurons or PC12 
cells has been shown (20,12). Assessing the effect of the SH2B1 mutations on these neuronal  
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Figure 3.2 Disruption of the PH domain changes the subcellular localization of SH2B1d and 
impairs the ability of SH2B1d to enhance NGF-induced neurite outgrowth. 
a) PC12 cells transiently expressing the indicated GFP-SH2B1d WT or GFP-SH2B1dDPR were 
imaged by confocal microscopy. b) Live PC12 cells transiently expressing GFP-SH2B1d WT or 
GFP-SH2B1dDPR were treated with 25 ng/ml mouse NGF for 2 days after which neurite 
outgrowth was assessed. GFP-positive cells were scored for the presence of neurites 2 times the 
length of the cell body (total of 300 cells per condition per experiment). The percentage of cells 
with neurites was determined by dividing the number of GFP-positive cells with neurites by the 
total number of GFP-positive cells. Means ± SEM, ****P<0.0001, n=3.  
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functions would broaden the scope of my work and give insight into whether the PH domain is 
important for neuronal function for other neurotrophic factors.  
 I have not yet been able to identify a mechanism by which the DPR mutation in the PH 
domain of SH2B1 impairs the ability of SH2B1b or SH2B1d to enhance neuronal differentiation.  
To continue to gain understanding of how the DPR deletion affects the function of SH2B1, future 
experiments in this project should focus on the following: 1) identifying binding partners of 
SH2B1, 2) determining the role of SH2B1 in gene expression, 3) determining if the DPR deletion 
affects neuronal projections that regulate energy balance, and 4) determining the effect of the 
DPR deletion on SH2B1 function in other tissues involved in energy balance and glucose 
homeostasis (liver, b-cells, fat). I have discussed these experiments in more detail in the 
following paragraphs.  
Identifying binding partners of SH2B1 in the nucleus 
Identifying binding partners of SH2B1b or SH2B1d  in the nucleus and how the DPR 
mutation affects the ability of SH2B1b and SH2B1d to enhance neuronal differentiation should 
further elucidate the role of SH2B1 in neuronal development. There are a number of proteins in 
the nucleus that regulate neurogenesis that may be affected by the PH domain mutations in 
SH2B1 (183). Phosphorylation of cellular proteins in response to NGF or BDNF in cells 
expressing WT or DPR mutant SH2B1b/d should be investigated. A global, non-biased 
phosphoproteomics approach can be used to identify cellular proteins whose phosphorylation is 
differentially altered by SH2B1 WT vs the SH2B1b or d DPR mutants. Phosphoproteomics 
might be particularly effective in identifying phosphoproteins whose phosphorylation is 
differentially regulated by SH2B1 b/d WT vs DPR, particularly if the DPR mutation has modest 
effects on signaling pathways that are amplified in more downstream targets.  Use of iTRAQ-
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based mass spectrometry will enable us to simultaneously analyze the results from different 
treatment groups, improving the ability to compare the phosphorylation sites identified. Priority 
should be given to proteins that are signaling proteins, proteins that regulate neurite outgrowth or 
other aspects of neuronal function, cytoskeletal proteins or proteins known to regulate 
cytoskeletal proteins (e.g. kinases, phosphatases) expected to affect neurite outgrowth, and 
nuclear proteins of potential relevance to the human disease phenotype. I would expect that 
phosphorylation of one or more of these proteins essential for neuronal differentiation would be 
altered in cells expressing mutant SH2B1b DPR or SH2B1δ DPR compared to WT SH2B1b or d 
respectively. 
Determining the role of SH2B1 in gene expression 
Another way to gain insight into how the DPR PH domain mutation affects the cellular 
function of SH2B1b would be to investigate gene expression.  A critical function of neurotrophic 
ligands is to initiate a highly-orchestrated response that alters the gene expression profile of 
neuronal precursors to promote differentiation into a mature neuron and formation of proper 
neuronal circuitry.  SH2B1b greatly enhances expression of a subset of NGF-regulated genes in 
PC12 cells (29).  Maximal stimulation appears to require nuclear cycling of SH2B1 (27,25) and 
is reduced by the P322S mutation for the two genes tested, Plaur and Mmp3 (Cline et al., 
personal communication).  However, exactly how SH2B1 regulates gene expression and how the 
pathogenic mutations in SH2B1 impair that regulation are not known. It would be interesting to 
test if the DPR mutation reduces the expression of NGF-regulated genes in PC12 cells. I would 
expect the DPR mutation to reduce the expression of NGF-regulated genes involved in neuronal 
differentiation and survival in PC12 cells.  To test this, I would propose to make PC12 cells 
stably expressing GFP, GFP-SH2B1b WT or GFP-SH2B1b DPR, treat the cells with or without 
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NGF, perform RNA seq and look for NGF- and SH2B1b-sensitive genes expressed differentially 
in DPR vs WT cells. 
I would next determine whether the PH domain mutations similarly affect expression of 
genes regulated by other neurotrophic ligands implicated in feeding behavior (e.g. BDNF) in the 
context of primary neurons. It could be particularly informative to determine the impact of the 
DPR mutation and other human obesity mutations on SH2B1 function in the context of BDNF. 
SH2B1 has been shown to interact with the BDNF receptor, TrkB, and to enhance the number of 
BDNF-induced neurite outgrowths in PC12 cells stably expressing TrkB and SH2B1b (7,182). 
More recently, overexpression of SH2B1β was shown to promote neurite outgrowth and 
branching in cultured hippocampal neurons supplemented with BDNF (20). Additionally, it 
would be interesting to study the roles of the other isoforms (α, γ, and δ) of SH2B1in BDNF 
signaling and the effect of any of the human obesity-associated mutations on BDNF function. I 
expect the human obesity mutations to have a bigger impact on SH2B1 regulation of BDNF than 
NGF signaling since BDNF is known to mediate signaling involved in the regulation of energy 
balance. Studying the effects of the different isoforms and the human mutations on BDNF 
signaling should provide critical insight into SH2B1 regulation of neuronal function critical for 
energy balance.  
Neuronal projections 
 Most experiments to elucidate the specific cellular functions of SH2B1 and to understand 
how the cellular functions are affected by human mutations in SH2B1 have used in vitro model 
systems. I showed that the ΔPR mutation impairs the ability of SH2B1 to enhance NGF-induced 
neurite outgrowth of cultured PC12 cells. However, it has not been determined whether SH2B1 
affects the ability to promote axonal projections and synapses in neurons implicated in energy 
 97 
balance in the hypothalamus. Based on previous lab findings implicating SH2B1 in neurite 
outgrowth, I predict that SH2B1 affects the neuronal projections from, or the number of neurons 
in, brain circuits that are involved in energy balance. The next experiment to carry out would be 
to define the role for SH2B1 in the control of circuit formation in neurons involved in energy 
balance.  
  In the hypothalamus, leptin activates LepRb on the surface of specialized neurons to 
control food intake and neuroendocrine processes that modulate energy expenditure.  The crucial 
role of leptin in the control of energy balance is underscored by the severe obesity in human 
patients and animal models with mutations in leptin or LepRb (184). Lifelong energy balance 
depends on the proper developmental formation of axonal projections from the LepRb-
expressing POMC and AgRP neurons in the arcuate nucleus to their crucial targets in the 
paraventricular hypothalamic nucleus (94). Disruption of Sh2b1 in LepRb neurons in mice 
promotes obesity and metabolic dysfunction, suggesting that SH2B1 signaling in LepRb neurons 
is crucial for the control of energy balance and metabolism (personal communication from L. 
Rui). I expect SH2B1 to play a role in the projection of leptin receptor-expressing neurons in the 
arcuate nucleus to the paraventricular hypothalamic nucleus based on previous findings that 
SH2B1 enhances neurite outgrowth in multiple types of neurons (185). Next, the impact of 
SH2B1 and the ΔPR PH domain deletion on the formation of POMC and AgRP circuits in the 
hypothalamus should be determined. Brain sections from these mice could be used for 
immunohistochemical analysis and fiber density can be determined.  I expect that the density of 
the AgRP and/or POMC projections to the PVH will be impaired.  
 BDNF has been shown to play a critical role in directing projections from TrkB 
expressing neurons in the arcuate nucleus to the paraventricular hypothalamic nucleus (186) and 
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SH2B1b enhances BDNF-dependent neurite outgrowth in PC12 cells (20).  Based on these 
findings, I hypothesize that SH2B1 in TrkB neurons is also crucial for establishing these circuits 
between the arcuate nucleus and paraventricular hypothalamic nucleus, and that this process may 
be dysregulated by the ΔPR and/or human mutations in SH2B1. To test this, I would generate 3 
sets of mice to look at the effect of SH2B1 on projections of TrkB neurons: WT, ΔPR and KO 
mice expressing tamoxifen-inducible mNeonGreen in TrkB neurons. I expect that the density of 
the AgRP and/or POMC projections to the PVH (or a subset) will be impaired in the Sh2b1 ΔPR 
and Sh2b1 KO mice compared to the Sh2b1 WT mice. It would also be interesting to examine 
whether the lack of SH2B1 in non-AgRP and non-POMC neurons impairs the projections of 
other TrkB neurons in the arcuate nucleus to other regions of the brain implicated in energy 
balance.  
Effect of DPR deletion in other tissues involved in energy balance and glucose homeostasis 
 Here, I show that in addition to becoming obese, the Sh2b1 ΔPR mice develop 
hyperglycemia, hyperinsulinemia, reduced glucose tolerance, and insulin resistance, a metabolic 
phenotype similar to that of the Sh2b1 KO mice. Whether the phenotype seen in the Sh2b1 KO 
mice is due to developmental abnormalities still remains to be determined. The Cre-lox system 
can be used to generate Sh2b1 conditional KO mice to delete SH2B1 in adulthood to determine if 
the phenotype is developmental, adult onset, or both. Furthermore, Cre-lox mice can also be used 
to delete SH2B1 in specific cell types in adulthood and determine the contribution of SH2B1 in 
these specific cells to the phenotype seen in the Sh2b1 KO mice.  Neuron-specific restoration of 
SH2B1b via the neuron-specific enolase promoter largely rescues the impaired glucose 
homeostasis seen in the SH2B1 KO mice (56). However, SH2B1 also binds via its SH2 domain 
directly to the activation loop of the insulin receptor (9,44,10) and deletion of SH2B1 inhibits 
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activation of the insulin receptor in liver, b-cells, and fat, including insulin-dependent tyrosine 
phosphorylation of IRS1 and IRS2 and activation of the PI3K/Akt and Erk1/2 pathways (41). 
These findings indicate that while neuronal SH2B1 is required for maintaining normal glucose 
homeostasis in vivo, peripheral SH2B1 may also be contributing to glucose homeostasis, at least 
in part, by enhancing IR activation and signaling in the liver, muscle, and/or fat. The mechanism 
by which the ΔPR or the P322S mutations in the PH domain of SH2B1 affect glucose 
homeostasis has not been extensively investigated. Whether the ΔPR deletion affects the 
activation of the insulin receptor and downstream targets should be tested in different tissues 
involved in glucose homeostasis (e.g. liver, b-cells).  
Glucose homeostasis may be dysregulated in one or more of these tissues in Sh2b1 ΔPR 
mice. In support of this, the ΔPR mice on standard chow exhibit increased liver weight and pale 
livers consistent with lipid accumulation. Increased lipid accumulation may be a factor 
contributing to impaired glucose metabolism, since high lipids have been shown to contribute to 
insulin resistance (187). To confirm that the increased liver weights in the ΔPR mice are due to 
increased lipid accumulation, H & E staining should be done. Triglyceride levels in the liver 
should also be measured.  I expect SH2B1 activation of the insulin receptor to be impaired and 
that the livers from Sh2b1 ΔPR mice will show increased lipid accumulation.  
 Several lines of evidence demonstrate that SH2B1 in b-cells is a novel pro-survival and 
pro-proliferative signaling molecule that directly promotes activation of the PI3K/Akt pathway 
in vitro and in vivo (142). Furthermore, SH2B1 has been proposed to sustain the ability of IRS 
proteins to activate the PI3K pathway by protecting IRS proteins from tyrosine 
dephosphorylation (48). Additionally, SH2B1 cell-autonomously promotes insulin expression by 
enhancing JAK2 activation and the ability of JAK2 to stimulate insulin promoter activity in b-
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cells (141). As a key experiment, the survival, proliferation, and insulin secretion in b-cells of 
the Sh2b1 ΔPR and P322S mice should be determined. Based on the published data of the role of 
SH2B1 in b-cells, I would expect the P322S and ΔPR mutations to impair the function of SH2B1 
in b-cells. 
Modeling of the PH domain of SH2B1 
 We analyzed the SH2B1 PH domain in the context of the NMR structure of the PH 
domain of the SH2B family member SH2B2/APS (179) to gain insight into potential alterations 
mediated by the mutants that we studied (Figure 8).  In the SH2B2/APS structure, the residues 
corresponding to P317, R318, and P322S in SH2B1 (P71, K72 and P76, respectively) lie on an 
exterior surface of the PH domain (Figure 2.18) that represents a likely binding interface (e.g., 
for a different region of SH2B1 or another protein).  Because the residues corresponding to P317 
and R318 in SH2B1 are on the surface of the PH domain and do not substantially change the 
direction of the loop, the P317, R318 deletion in SH2B1 is not expected to severely damage the 
structure, although the deletion would be expected to substantially alter the shape of the interface 
surface. The P317, R318 deletion is also predicted to possibly affect the ability of nearby S320 to 
be phosphorylated. I am now trying to determine whether a change in the ability of S320 to be 
phosphorylated is contributing to the cellular and physiological phenotype seen with the ΔP317, 
R318 deletion. In preliminary studies, mutating S320 to an alanine, thereby preventing 
phosphorylation at this position, did not alter the subcellular localization of SH2B1b or SH2B1b 
DPR nor did it affect the ability of SH2B1b or SH2B1b DPR to promote NGF-induced neurite 
outgrowth.  I am confirming these results and testing whether mutating S320 to the 
phosphomimetic E320 alters either the subcellular localization of SH2B1b or SH2B1b DPR or 
their ability to promote neurite outgrowth.  
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 In summary, carrying out these experiments will provide important insight into how the 
different SH2B1 isoforms act to regulate growth factor signaling, gene expression, neuronal 
circuits and peripheral tissues involved in energy balance and glucose metabolism and how they 
are affected by the P322S mutation and DPR disruption in the PH domain of SH2B1. Further 
understanding of the mechanism of action of SH2B1 may provide basis for therapeutic 
intervention to treat obesity and/or insulin resistance in humans. 
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